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ABSTRACT 
 
New chemotherapeutics are urgently needed to combat Mycobacterium tuberculosis (Mtb), the 
causative agent of tuberculosis (TB). The development of compounds that could potentiate the 
activity of known antimycobacterial drugs is a relatively unexplored approach to new TB drug 
discovery. This study aimed to generate metabolites of chlorpromazine (CPZ), a phenothiazine 
with demonstrated in vitro activity against Mtb, and to investigate their potential utility in 
combination with anti-TB drugs. 7-HydroxyCPZ (M2), CPZ-N-oxide (M3), CPZ sulfoxide (M1), 
nor-CPZ (M5), nor-CPZ sulfoxide (M6b) and CPZ-N-S-dioxide (M4b) were generated from CPZ 
using various biotransformation systems and identified by Liquid Chromatography - Mass 
Spectrometry (LC/MS). The identity of M2 was confirmed with reference to a 7-hydroxyCPZ 
standard. M3, M1, M5, M6b and M4b were synthesized de novo and used to identify the 
metabolites generated in the biotransformation samples. Individually, CPZ and its metabolites 
(M2, M3, M5) were weakly active (MIC99 >50µM) against M. smegmatis (Msm) and Mtb while 
M1, M6b & M4b did not exhibit a MIC99 even at very high concentrations. Generally, an 
improvement in activity was observed where CPZ or its metabolites were used in combination 
with known anti-TB drugs. The combinations that exhibited a fractional inhibition concentration 
index (FICI) of < 0.5 were defined as synergistic. A combination of M2 and spectinomycin 
(SPEC) exhibited the highest synergism against Msm (FICI 0.19) and Mtb (FICI 0.13). In vitro 
assays established that CPZ and M2 are bactericidal against Mtb whereas M3 and M5 are 
bacteriostatic on their own. In combination assays, the use of RIF with M3 and M5, bedaquiline 
(BDQ) with M2, and SPEC with M3 were bactericidal. At 140µM, CPZ and M1, M2, M3 treated 
samples exhibited a 2-fold up-regulation of the cydA (Rv1623c) gene which encodes an 
essential subunit of the cytochrome bd-type menaquinol oxidase in Mtb. The same observation 
xxiii 
 
was made for RIF/M2 and RIF/M5 treated samples. These results suggest that the metabolites 
retain the mechanism of action (MoA) as the parental CPZ. The Mtb 16S rRNA gene, rrs 
(MTB000019) was identified as the biological target for SPEC. This brought into perspective the 
underlying mechanisms at play when SPEC is used in combination with CPZ, its metabolites or 
other drugs, against mycobacteria. This study establishes the utility of combination assays in 
confirming the active metabolite(s) of known drugs and provides proof of concept data to 
support follow-up investigations of CPZ and its metabolites as potential compounds for novel 
combination therapies for anti-TB drug development. 
 
 
1 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
1.1 Background 
Tuberculosis (TB) remains a global health problem. Since the identification in 1882 of 
Mycobacterium tuberculosis (Mtb) as the causative agent of TB, the epidemic continues 
unabated. It is estimated that every year, approximately 9 million people develop active TB, 
30%  of which reflect co-infection with HIV.1–3 According to the World Health Organization 
(WHO) 2014 report, the majority of TB cases worldwide are in the South-East Asia (29%), 
African (27%) and Western Pacific (19%) regions. The report indicates that India and China 
alone accounted for 26% and 12% of total cases, respectively (Figure 1.1). The TB incidence 
rate at country level ranges substantially, with around 1000 or more cases per 100 000 people 
in South Africa and Swaziland, and fewer than 10 per 100 000 population in parts of America, 
several countries in western Europe, Japan, Australia and New Zealand.3–5  
 
Some shortcomings of the current treatment strategies for TB include limited effectiveness of 
public health systems, particularly in resource-poor countries where the main TB burden lies. 
The ease with which TB infection spreads by inhalation of a few droplet nuclei (2-5µm in 
diameter) containing  as few as 1-3 bacilli, has helped to sustain this scourge at current levels.6  
 
 
CHAPTER 1 
2 
 
 
Figure 1.1 Estimated global TB prevalence3,4,7 
 
 
1.2 Mtb pathology and physiology  
Significant progress has been made in the molecular characterization of the pathogen but more 
work is still needed to understand how Mtb copes with the numerous environments it 
encounters in the course of a successful infection.  
 
Mtb has a doubling time of ∼20h in vitro in contrast to most bacteria that divide much more 
rapidly. Naturally one would assume that, since antibiotics primarily work on cells that are 
actively dividing, the overall duration of therapy might somehow correlate with the length of the 
growth cycle. However, this is not the case: antibiotics are able to eliminate actively dividing 
bacilli in vitro, but a number of factors - including drug penetration8,9 and the ability of the 
bacillus to enter into states of antibiotic tolerance10 and extended phases of slow or non-
replication11 ensure that the current combination regimen must be continued for several months 
to minimize the risk of treatment failure and/or recurrence.12 
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The persistence of Mtb within the human population depends on its ability to cycle through 
repetitive phases of infection, disease, transmission, and clinical latency. Mtb affects the lungs 
(pulmonary TB) but can affect other sites as well (extrapulmonary TB). It uses diverse strategies 
to survive and replicate within human macrophages, and to evade immune surveillance1,13 
where the initial interaction between host phagocytic cells and microbial pathogens is mediated 
by specific phagocyte membrane receptors and ligands present on the microbe. Mtb replicates 
intracellularly within human macrophages by preventing phagosomal maturation and modulates 
other macrophage defenses to promote its survival.14 
 
In addition, Mtb possesses a sophisticated metabolic system that supports the biosynthesis of 
all essential amino acids, vitamins, and enzyme co-factors.15 It is also able to oxidize multiple 
carbon substrates, and to utilize a variety of alternate electron transport chains during 
adaptation to variable host environments. Its unusual cell wall - rich in lipids and impermeable to 
most compounds - ensures inherent resistance to host immune effectors and numerous 
antibiotic agents, while an array of transcriptional regulators enables a rapid response to 
environmental cues. The bacillus is also armed with multiple defense and detoxification 
pathways, as well as DNA repair and maintenance functions.15,16  
 
The bacterium is adept at escaping host defense mechanisms in macrophages, and the 
immune response to infection results in the formation of granulomatous lesions that become 
caseous and hypoxic, conditions in which the drugs are unable to penetrate or be effective.12 
 
1.2.1 Development of drug resistance in Mtb 
Despite an in-depth understanding of how Mtb evolves and overcomes the inhibitory effect of 
anti-TB drugs,17,18 development of resistance has been a major impediment to the treatment of 
TB. Enormous amounts of money have been directed into drug development programs to 
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discover new anti-TB agents in a bid to overcome this problem.15 Multidrug-resistant TB (MDR-
TB) is defined as resistance to the first-line drugs, isoniazid (INH) and rifampicin (RIF); 
extensively drug-resistant TB (XDR-TB) is MDR-TB with additional resistance to 
fluoroquinolones and at least one of the injectable second-line drugs [capreomycin, kanamycin 
(KANA), and amikacin (Figure 1.2)].1,19 It is reported that 5.4% of MDR-TB cases are XDR-TB.1 
On the other hand, extremely drug resistant (XXDR-TB) and totally drug-resistant TB (TDR-TB) 
are terms used to describe resistance to all first-line and second-line anti-TB drugs.19 These 
drug resistant infections are treated by a combination of eight to ten drugs with therapies lasting 
up to 18–24 months that can result in side-effects including nephrotoxicity and ototoxicity with 
aminoglycosides, hepatotoxicity with ethionamide and dysglycaemia with gatifloxacin.1  
 
1.2.1.1 Intrinsic resistance 
Intrinsic resistance refers to the mycobacterium’s ability to overcome the inhibitory effect of anti-
TB agents through its inherent structural or functional characteristics.20 Intrinsic drug resistance 
in Mtb is thought to be associated primarily with its unique cell wall properties such as the 
presence of mycolic acids, which are high-molecular-weight α-alkyl,β-hydroxy fatty acids 
covalently attached to arabinogalactan,  that constitute a very hydrophobic barrier responsible 
for resistance to certain antibiotics.21 In addition, Mtb possesses β-lactamase enzymes, which 
confer intrinsic resistance to β-lactam antibiotics, while efflux mechanisms contribute to 
resistance to antibiotics such as INH, RIF, tetracycline, linezolid, Bedaquiline (BDQ), 
fluoroquinolones and aminoglycosides.19,22,23 Low antibiotic permeabilitiy through the Mtb cell 
wall may also occur in non-replicating bacilli resulting in another form of phenotypic drug 
resistance that is independent of efflux.24,25 
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1.2.1.2 Acquired drug resistance 
Acquired drug resistance occurs when Mtb obtains the ability to resist bioactivity of a particular 
antimicrobial agent to which it was previously susceptible. The resistance is caused mainly by 
spontaneous mutations in chromosomal genes, and the selective growth of such drug-resistant 
mutants may be promoted during sub-optimal drug therapy which arises from non-adherence to, 
or improper use of, medication by TB patients – as well as from the potential for antibiotics to 
establish concentration gradients across differentially permeable anatomical and pathological 
loci.8 Monotherapy will in most cases result in development of resistance as the bacilli undergo 
genetic mutations to overcome the effectiveness of the drug administered singly. In addition, 
non-adherence to TB medication prescribed as combination therapy will in most cases result in 
a relapse of the disease that results from lack of clearance of the bacteria during the first two 
months of treatment, and presence of lesions in the lung where the tissue has been destroyed 
and surrounded by a thick fibrotic wall. It may also lead to the emergence of genetic drug 
resistance, resulting in an even longer treatment duration with less effective and more toxic 
second-line and third-line drugs.8,9 Nevertheless, proper use and completion of TB treatment by 
patients as recommended in the DOTS (Directly Observed Therapy, Short Course) program 
(section 1.3.1) may reduce the risk for development of acquired drug resistance. However, 
studies have established that even with all the controls in place TB drug resistance has not 
been fully contained.19,26,27  
 
1.3 TB control 
1.3.1 DOTS (Directly Observed Therapy, Short Course) 
In response to the global TB epidemic, the WHO developed a control strategy largely based on 
the pioneering work of the British Medical Research Council (BMRC) and the International 
Union against Tuberculosis and Lung Disease (IUATLD). This strategy is known as DOTS.28 
The essential elements of DOTS are as follows:  
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 Strong government commitment to TB control.  
 Diagnosis by smear microscopy (or by culture where resources permit). 
 Standardized short course chemotherapy with directly observed treatment for at least 
the first 2 months. 
 Secure supply of safe, high-quality drugs. 
 Individual reporting of treatment outcome and monitoring of program performance. 
 
A bench-mark was set for this program where the goal was to achieve a significant reduction in 
the burden and incidence of TB globally by 2015, a target set within the United Nations (UN) 
Millennium Development Goals (MDGs). Since the global rollout of the DOTS strategy, a 
cumulative total of 56 million people were successfully treated for TB between 1995 and 2012, 
saving approximately 22 million lives.3 However, many concerns have been raised over the 
effectiveness of the strategy owing to the fact that, despite the successful implementation of the 
program, the TB burden in Africa and Asia has not been fully contained.28  
 
1.3.2 TB vaccine  
TB is one of the diseases for which there is still no effective vaccine for the general population. 
However, the live attenuated vaccine derived from M. bovis, which is known as bacille Calmette-
Guerin (BCG), has been critical in preventing the disease in children. Regrettably, being the 
only vaccine in existence it has shown variable efficacy globally especially against pulmonary 
disease in adolescents and adults. Since the development of BCG, no other vaccine has made 
it into the market. However, several candidate vaccines are currently in clinical trials. Much is 
still not understood about BCG which requires further research.29,30  
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1.3.3 Anti-TB drugs, their mechanisms of action (MoAs) and development of resistance 
Treatment of drug-susceptible (DS)-TB involves an initial phase of INH, RIF, pyrazinamide 
(PZA) and ethambutol (EMB) (Figure 1.2) for the first 2 months followed by a continuation phase 
of INH and RIF for a further 4 months. BDQ, recently discovered after 40 years since the known 
anti-TB drugs were developed, is currently being used for treatment of MDR-TB. It is normally 
introduced to the standard TB treatment regimen and administered for a maximum duration of 6 
months.3,31 
 
Up to 95% of people with DS-TB can be cured in 6 months with the four drug regimen. WHO 
recommends use of fixed-dose combinations of TB drugs because they are thought to prevent 
acquisition of drug resistance due to monotherapy, which may occur with individual 
(“unprotected”) drugs.3 These drugs can be grouped into various classes based on their MoA. 
Generally, many antibiotics are either bactericidal (kill the bacterium) or bacteriostatic (inhibit 
growth and replication of the bacterium). The demonstrated efficacy of the oxazolidinone  
(linezolid), in treating clinical drug-resistant TB indicates that bacteriostatic drugs are as 
important as those which are bactericidal; however, in the case of the former, the host’s immune 
mechanism must come into play in order to clear the infection.32    
 
The future of TB therapy must be one in which treatment time is reduced to only a few months 
or, better still, a few weeks. The reasons why this is difficult to achieve when other bacterial 
infections are cured in a matter of days or weeks are probably numerous, certainly very poorly 
understood, and relate to the biology of the organism, the host response to infection and the 
properties of the available drugs.  
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Figure 1.2 First- and second-line drugs for TB treatment 
 
1.3.3.1 Rifamycins 
Rifamycins (Figure 1.3) were first discovered in the 1950s through biosynthesis by the 
bacterium Amycolatopsis mediterranei. In the mycobacteria, this group of compounds inhibit 
RNA synthesis by forming a stable complex with RNA polymerase binding with the β-subunit 
(encoded by rpoB) causing an effect on the nucleic acid metabolism and eventually leading to 
cell death.33 Amongst all antibiotics used clinically, the MoA is unique to this class of 
compounds. Examples include RIF, rifabutin, rifalazil, rifapentine among others.34 It is reported 
that development of resistance to RIF in Mtb occurs as single point mutations in the rpoB gene, 
which encodes the β-subunit of RNA polymerase.19,33,35  
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Figure 1.3 Examples of rifamycins (1st line TB drugs) 
 
 
1.3.3.2 Fluoroquinolones 
These drugs (Figure 1.4) are broad-spectrum antibacterials that were discovered by chance 
during the synthesis of chloroquine. Nalidixic acid was the first generation quinolone to be 
developed in 1962 and was used for urinary tract infections. Subsequently, other generations of 
this family of compounds were later developed and examples include ofloxacin, ciprofloxacin, 
pefloxacin (2nd generation), levofloxacin, sparlofloxacin, balofloxacin (3rd generation) and 
gatifloxacin, moxifloxacin, prulifloxacin (4th generation).36,37 The drugs are only used in cases of 
drug resistance and in combination with other anti-TB drugs. Fluoroquinolones are second-line 
anti-TB drugs but, in combination with various first-line antituberculosis drugs, have shown 
greater ex vivo antimycobacterial activity in macrophages than the individual drugs alone38. 
Their antibacterial MoA is due to an inhibition of an ATP-dependent DNA gyrase.39–44 Mutations 
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in the conserved quinolone resistance-determining region (QRDR) of gyrA and gyrB leads to 
development of resistance to fluoroquinolones in Mtb. 39,44–46 
 
 
Figure 1.4 Examples of fluoroquinolones (2nd line TB drugs) 
 
 
1.3.3.3 Aminoglycosides 
In this class of compounds (Figure 1.5), streptomycin (STRP, an amino cyclitol) was the first to 
be discovered in 194447 leading to further discoveries of other aminoglycosides from nature. Mtb 
mutants resistant to STRP were identified 2 years after the discovery of the drug, however, it is 
still used in TB combination therapy as a 2nd line drug. Through semi-synthesis, medicinal 
chemists have been working towards making analogues that are less prone to development of 
resistance and with superior biological activity. The MoA of aminoglycosides is through inhibition 
of either of the two ribosome subunits 50S and 30S, which are responsible for protein synthesis 
in mycobacteria. 50S ribosome inhibitors include macrolides (erythromycin), lincosamides 
(clindamycin), amphenicols (chloramphenicol) and oxazolidinones (linezolid) while examples of 
the 30S inhibitors include tetracyclines and amino cyclitols (KANA and gentamicin).31,40,48,49   
 
CHAPTER 1 
11 
 
It has been shown that resistance to aminoglycosides in Mtb occurs by mutation of the ribosome 
target binding sites specifically, mutations in the rpsL gene, which encodes the ribosomal 
protein S12, account for approximately half of all STRP-resistant clinical isolates with the K43R 
mutation predominating. In about 20% of STRP-resistant Mtb clinical isolates, such resistance is 
associated with mutations in the rrs gene.50–52 Mtb Eis (enhanced intracellular survival) protein 
reported to suppress host immune defenses by negatively modulating autophagy, inflammation, 
and cell death through c-Jun N-terminal kinase (JNK)-dependent inhibition of reactive oxygen 
species (ROS) generation, has also been demonstrated to contribute to drug resistance by 
acetylating multiple amines of aminoglycosides, rendering them inactive.53,54 
 
 
Figure 1.5 Examples of aminoglycosides (2nd line TB drugs) 
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1.3.3.4 Isoniazid (isonicotinylhydrazine, INH) 
INH (Figure 1.2) is a 1st line anti-TB drug that has been very effective since its development. 
INH inhibits the synthesis of the mycolic acids that form the long chain fatty acids which 
contribute to the structural composition of the cell wall.55–57 The biological activity of INH 
requires activation from a pro-drug state by the mycobacterial catalase-peroxidase enzyme, 
KatG, which couples the isonicotinic acyl with NADH to form isonicotinic acyl-NADH complex 
leading to antimycobacterial effect. Activation of INH is also reported to form other derivatives 
such as reactive nitrogen intermediates, which are also associated with the antimycobacterial 
activity of the drug.40,55,58–60 Mutations in INH resistant clinical isolates are most commonly 
detected in the KatG gene, occurring in 50–80% of cases, thus reducing the ability of the 
catalase-peroxidase to activate the INH pro-drug.60,61 It is also reported that, in a few cases, INH 
resistance may also arise from mutations in inhA, resulting in reduced affinity of the enzyme for 
NADH without affecting its enoyl reductase activity, or in the promoter region of the mabA-inhA 
operon, resulting in over expression of the wild-type enzyme.62  
 
1.3.3.5 Pyrazinamide (PZA) 
PZA (Figure 1.2) is a 1st line TB drug which was developed in the mid-1980s. Structurally, it is 
similar to INH. It is a pro-drug, hydrolyzed intracellularly to pyrazinoic acid by pyrazinamidase 
(Pzase) encoded by pncA.63,64 Interestingly, PZA is bactericidal against non-replicating bacilli 
but bacteriostatic against fast replicating organisms.31,40 It does not exhibit activity in vitro on 
many mycobacterium strains but shows very high efficacy in vivo. PZA was found to be active 
against Mtb only at an acidic pH (e.g. 5.5), which is thought to occur during active inflammation 
due to production of lactic acid by inflammatory cells as a key defence strategy in macrophages. 
This makes PZA a unique drug considering that its development has not been in accordance 
with the conventional drug discovery process: it wouldn’t be identified in most current drug 
screening algorithms. When added to the current TB regimen, it reduces the duration of 
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treatment significantly from 9 to 6 months.40,65 Though its MoA has been elusive, Shi et al.63 
identified the ribosomal protein S1 (rpsA) as a target for pyrazinoic acid. The protein is vital for 
protein translation and the ribosome-sparing process of trans-translation that is responsible for 
execution of large changes in the genetic programs, including responding to stress, 
pathogenesis and differentiation. Development of resistance to this drug is associated with 
mutations in the pncA gene in Mtb. Other possible points of mutations include deficient uptake, 
enhanced efflux, or altered pncA regulation.64,66   
 
1.3.3.6 Ethionamide 
Structurally, ethionamide (Figure 1.6) is also related to INH. It is a pro-drug that was discovered 
in 1956. It requires activation to form sulfinic acid by ethA, a monooxygenase in Mtb, and binds 
NAD to form an adduct which inhibits inhA in the same way as INH leading to inhibition of 
mycolic acid synthesis.67–69 Development of resistance to ethionamide is attributed to mutations 
in ethA or inhA. Other likely mutations of mshA a gene encoding the first enzyme involved in the 
biosynthesis of mycothiol, a major low-molecular-weight thiol in Mtb, and thought to also be 
involved in activation of ethionamide, could occur leading to development of resistance to 
ethionamide.67,68,70  
 
 
Figure 1.6 Ethionamide 
 
1.3.3.7 Ethambutol (EMB) 
EMB (Figure 1.2) was discovered in 1961 and kills actively multiplying bacilli by inhibiting 
arabinosyl transferases involved in cell-wall biosynthesis in mycobacteria.71 It is included 
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amongst the four drugs in the current TB regimen and this is due to the fact that, in combination 
with some anti-TB drugs, it results in synergy, has low toxicity and is effective in arresting 
development of resistance. Development of resistance of EMB in Mtb is associated with point 
mutations in the embBC. Commonly observed multistep mutations in embB codon 306 followed 
by mutations in pathways for the biosynthesis (Rv3806c) or use (Rv3792) of the cell wall 
precursor decaprenylphosphoryl-β-D-arabinose (DPA), which, finally, are followed by mutations 
in embC, have been reported to be associated with variable degrees of EMB resistance. 72–75  
 
SQ109 (Figure 1.7) as well as other analogues of EMB have been reported to exhibit similar 
activity to EMB but with a different MoA that involves inhibition of the enzymes involved in 
menaquinone synthesis, respiration, and, hence, ATP synthesis.76 It is also reported that, 
SQ109 acts as an uncoupler, collapsing the proton motive force (PMF). This inhibition is thought 
to indirectly impact on a particularly vulnerable and druggable target mmpL3 gene, which 
encodes a trans-membrane trehalose monomycolate (TMM) transporter, MmpL3 involved in 
exporting mycolic acids to the cell membrane. The latter was initially thought to be the sole 
target for SQ109.77,78  
 
 
Figure 1.7 Ethambutol (EMB) analogue 
 
1.3.3.8 Bedaquiline (BDQ) 
The diarylquinoline, BDQ (also known as TMC207, Figure 1.8), is the first new  anti-TB drug to 
be developed in 40 years.3 It is highly active on non-replicating bacilli of drug-susceptible, MDR 
and XDR Mtb strains, with no cross-resistance to current first-line drugs. It is therefore added to 
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the TB treatment regimen only for drug resistant infections.3,31,79 BDQ inhibits ATP synthase, 
blocking ATP generation in Mtb.80 When tested alone, BDQ was reported to have similar 
antimycobacterial activity to a combination of three members of the standard anti-TB regimen 
(RIF, INH and PZA) and it was more effective than RIF alone in mouse models.19 Resistance to 
BDQ is mediated by mutations in the atpE gene encoding the trans-membrane and oligomeric C 
subunit of ATP synthase. However, recent reports indicate that a majority of in vitro-generated 
mutants, resistant to BDQ lack mutations in atpE, suggesting that there are other mechanisms 
of drug resistance.81,82  
 
 
Figure 1.8 Bedaquiline (BDQ) 
 
1.3.3.9 para-Aminosalicylic acid 
This anti-TB drug (Figure 1.9) is widely used clinically, and was discovered in the 1940s. It is a 
pro-drug that is activated by dihydropteroate synthase (DHPS) and dihydrofolate synthase 
(DHFS) to a hydroxyl dihydrofolate.83 The active form of the drug is reported to inhibit 
dihydrofolate reductase (DHFR) involved with folic acid biosynthesis.84 Initially, resistance to this 
drug in Mtb was reported in clinical isolates where mutations in the thyA gene encoding the 
enzyme thymidylate synthase of the folate biosynthesis pathway were established, signifying 
that MoA of the drug may be as speculated84 but more recent studies established that inhibition 
of DHPS or mutation in DHFS prevents the formation of the hydroxyl metabolite, hence 
conferring resistance to para-aminosalicylic acid.83,85  
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Figure 1.9 para-Aminosalicylic acid 
 
1.3.4 Repurposing and repositioning of old drugs for anti-TB drug development 
Finding new uses for old drugs is referred to as repurposing. For example, a drug known to treat 
fungal infections can also exhibit antibacterial properties and can hence be developed as an 
antibiotic. On the other hand, repositioning refers to the process of carrying out structure 
modifications on an old drug to acquire different biological properties.86  Lately, these strategies 
have been integrated into the drug discovery process, for the following reasons: rescuing stalled 
pharmaceutical projects, finding treatments for neglected diseases and to reduce the risk, 
enormous amounts of money, manpower and time that are required to develop a novel drug.87 
This section discusses some classic examples of drugs that have the potential or are in the 
process of either being repositioned or repurposed for use as anti-TB agents.  
 
Macrolides such as clarithromycin (Figure 1.10) are broad spectrum antibiotics consisting of a 
macrolide ring, to which one or more deoxy sugars may be attached. The ring is associated with 
the compounds’ bioactivity specifically binding to the bacterial 50S ribosomal subunit and 
inhibiting RNA-dependent protein synthesis.88–90 The antimycobacterial activity of this class of 
compounds against Mtb is reported to be weak.91,92 These drugs are normally faced with 
intrinsic resistance in Mtb attributed to low cell wall permeability, a property that is not found in 
non-tuberculous mycobacteria.19 Clarithromycin is a good example of a macrolide that is 
reported to exhibit in vitro antimycobacterial activity but not in vivo.92  
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Capreomycin (Figure 1.10) is a macrocyclic polypeptide antibiotic isolated from Streptomyces 
capreolus that has also been shown to have antimycbacterial activity against MDR-TB. The 
drug interferes with several ribosomal functions by binding to the 16S rRNA helix 44. Resistance 
to this drug in Mtb is associated with mutations in the rrs gene encoding 16S rRNA.19,49,93 
 
Another antibiotic, cycloserine (Figure 1.10) is a D-alanine analogue that has antimycobacterial 
activity against Mtb. Interestingly, the drug has an effect on the central nervous system making 
it suitable as an anti-TB drug for psychiatric patients.94 The MoA in Mtb involves interruption of 
peptidoglycan synthesis by inhibiting the enzymes D-alanine racemase (alr) and D-alanine:D-
alanine ligase (ddl) necessary for the synthesis of UDP-muramyl-pentapeptide.95 More recent 
studies have established that ddl is the primary target of cycloserine, as cell growth is inhibited 
when the production of D-alanyl-D-alanine is halted. It was shown that inhibition of alr may 
contribute indirectly by lowering the levels of D-alanine, thus allowing cycloserine to outcompete 
D-alanine for ddl binding.96 Development of resistance was reported in Msm and M. bovis 
mainly due to over expression of alrA and ddl although whether similar mechanisms are 
responsible for cycloserine resistance in Mtb remain to be investigated.95  
 
An interesting class of compounds that have been discovered to combat anaerobic bacterial 
and parasitic infections is the nitroimidazoles (Figure 1.10). In Mtb, metronidazole is reported 
to be active under anaerobic conditions, contrary to the effect observed for INH and RIF.97,98 In 
vivo studies have only revealed the antimycobacterial activity of metronidazole in Mtb-infected 
rabbits.99 Econazole and clotrimazole are thought to inhibit the P450 mono-oxygenase 
homologue to the eukaryotic 14α-sterol demethylases and that the imidazole moiety binds the 
iron of these haem-containing enzymes. 100 
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Figure 1.10 Examples of drugs with potential anti-TB properties 
 
PA-824 (Figure 1.11) is a bicyclic nitroimidazopyran related to metronidazole, exhibiting 
bactericidal activity against replicating and hypoxic Mtb.101 It is highly active against MDR 
clinical isolates of Mtb, suggesting no cross-resistance with current anti-TB drugs; better still, 
PA-824 inhibits a new target in tubercle bacilli. It is also reported to have antimycobacterial 
activity against Mtb in murine and guinea pig models. The compound is a pro-drug that is 
activated by a cofactor F420-dependent glucose-6-phosphate dehydrogenase (Fgd) and 
deazaflavin-dependent nitroreductase (Ddn). PA-824 rapidly disrupts the oxidation of 
hydroxymycolates to ketomycolates with concomitant accumulation of hydroxymycolates, a 
class of mycolic acids that are major constituents of the cell envelope of Mtb. Resistance to PA-
824 is most commonly mediated by mutations that lead to loss of pro-drug activation, including 
those in the genes Rv0407 (fgd) and Rv3547 (ddn) which encode the activating enzymes. 101,102 
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Delamanid (OPC-67683) (Figure 1.11) is derived from the nitro-dihydro-imidazooxazole class of 
compounds. It exhibits high in vitro activity against drug-susceptible and resistant Mtb strains 
and does not show cross-resistance to any current first-line drugs. It is also reported to have 
antimycobacterial activity with evidence that infrequent and low dosing may be effective. OPC-
67683 has a long half-life, is not metabolized by cytochrome (CYP) enzymes and its efficacy in 
immune-compromised mice suggest that this drug may be useful for the treatment of co-infected 
TB/HIV patients. Similar to PA-824, the pro-drug OPC-67683 is converted to its active form by 
deazaflavin (cofactor F420) dependent nitroreductase (ddn) resulting in multiple highly reactive 
species that inhibit the synthesis of mycolic acids. Development of resistance to delamanid is 
attributed to mutations in the Rv3547 (ddn) gene, indicating defective drug 
activation.19,79,86,101,103,104 
 
 
Figure 1.11 PA-824 and delamanid 
 
 
Spectinomycin (SPEC, Figure 1.12) is an aminoglycoside produced by the bacterium S. 
spectabilis and used to treat gonorrhea.105,106 A recent structure activity relationship (SAR) study 
of SPEC resulted in derivatives known as spectinamides (Figure 1.12) with 50-fold higher 
antimycobacterial activity against sensitive and resistant strains of Mtb (MIC 0.8-1.6 & 1.6-3.1 
µg/ml respectively). Absence of cross-resistance with anti-TB drugs was reported for this new 
class of compounds and most importantly the compounds were said to overcome efflux pumps 
in Mtb.107  
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Figure 1.12 Examples of spectinamides 
 
Phenothiazines (Figure 1.13) are antipsychotic drugs that were later discovered to have 
antimycobacterial activity. Methylene blue was the first compound to be identified with 
antibacterial and antiparasitic activity though it caused lethargy in humans and further 
development was channeled towards treatment of psychosis. Interestingly, it was noted that in 
hospital wards, patients treated with chlorpromazine (CPZ) exhibited lower bacterial infections 
than other normal patients.108–110 This observation was not explored for many years until 
recently when a paradigm shift occurred in drug development resulting in repurposing and 
repositioning of old drugs for new uses.86,108,111 Thioridazine and CPZ have been reported to be 
active against actively replicating or latent, drug-susceptible and drug-resistant Mtb.112 However, 
due to side effects in humans,113–115 serum concentrations above the MIC for Mtb cannot be 
safely attained. Nevertheless, against phagocytosed Mtb in macrophages, the killing 
concentration of thioridazine was reported to be as low as 0.1mg/L, 10-20% lower than the 
concentration used clinically in the treatment of psychosis indicating that clinical use of the drug 
is possible. This was attributed to the drug concentrating effect of the 
macrophages.110,113,114,116,117 Thioridazine has also been demonstrated to have MDR and XDR 
antimycobacterial activity in mice.108,110,112,118–120 Moreover, in a study carried out by Abbat et 
al.121 on TB infected patients, addition of thioridazine to a regimen of anti-TB therapy led to 
faster culture conversion of sputum and lack of relapse.  
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The MoA of phenothiazines is reported to be involved in inhibition of the electron transport 
pathway,122,123 specifically targeting NADH:menaquinone oxidoreductase activity, which is 
responsible for aerobic respiration of mycobacteria.124 It is also thought that the compounds act 
on enzymes involved in fatty acid metabolism and membrane proteins, particularly efflux pumps 
causing synergism when combined with other drugs such as anti-TB drugs and other antibiotics. 
As of now, no mechanisms of resistance for this class of compounds has been 
reported.19,111,113,117,124–126  
       
 
Figure 1.13 Examples of phenothiazines 
.                                  
 
These studies are a clear demonstration of how drugs can be repurposed and/or repositioned 
for use for treatment of TB. 
 
1.4 Drug discovery via biotransformation 
To overcome drug-discovery challenges especially in areas such as TB, alternative strategies 
need to be explored in order to augment and complement the conventional drug-discovery 
paradigm. The conventional strategies mainly involve the synthesis or isolation of novel 
chemical entities from natural products. A different approach involves the use of 
biotransformation in the development of drugs that are based on the active metabolite(s) of 
parental compounds with demonstrated efficacy. In a drug development program, the use of 
biotransformation is relevant especially when there exists no chemical synthesis solution. This is 
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driven by the chemo- regio- and enantioselectivity of enzymes which operate at near neutral pH, 
ambient temperatures and atmospheric pressures; industrially useful chemistry often requires 
extremes of these conditions.127,128  
 
Metabolism is the process that converts compounds into chemicals that can be more readily 
eliminated from the body.129 Where the parental compound is a drug, the products of 
metabolism can include those metabolites which are active against the same pharmacological 
target as the parental molecule.128,130–132 The formation of pharmacologically active metabolites 
is usually mediated by two mechanisms: phase I metabolism, which includes oxidation, 
reduction, and hydrolysis, and phase II, which occurs via conjugation reactions. Phase I 
metabolism mediated by CYP450 enzymes is the most common pathway.129–131 By definition, 
the metabolism of the active metabolite(s) itself will lead to the formation of fewer total 
metabolites than will be obtained from the parent compound. Consequently, the use of an active 
metabolite as a drug may reduce the possibility of off-target toxicity that can be caused by one 
or more extra metabolites formed from the parent compound.130–132 That is, the number of 
metabolites that can be generated from the applied drug should limit the possibility for unwanted 
effects which can result from the inhibition of essential host functions.133 
 
Some years back, the chemical and structural characterization and elucidation of the 
metabolites derived from novel lead compounds was often not completed until late in the drug 
development process. It is at this point that the relative contribution of active metabolites to the 
overall observed therapeutic effect was evaluated. In some cases, a full assessment of the 
pharmacological significance of metabolites was not made until after drugs had reached the 
market.131 Even as technological advances have made early determination of biotransformation 
profiles feasible, biological transformation as a method of drug design has not been widely 
exploited.130,134 Nevertheless, pharmacologically active metabolites have in some instances 
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been successfully developed as drugs, and these often possess superior physicochemical, 
pharmacodynamics and pharmacokinetic properties compared to the parent drugs (Table 
1.1).128,130–132 para-Acetamidobenzenesulfonamide, a metabolite of prontosil which is a dye and 
a pro-drug, discovered in mice, was the first sulfonamide antibiotic to be developed.135 However, 
it is worth noting that, there are no reports of antibiotics developed from active metabolites of 
antibacterial compounds. This creates a research opportunity for medicinal chemists especially 
in the area of TB research.  
 
Table 1.1: Marketed drug metabolites and their parents 
Parent  Metabolite (active, marketed) Use of the 
marketed 
metabolite 
 
 
mucokinetic 
agent and 
topical 
anesthetic 
  
antipsoriatic 
 
 
antihistamine 
 
 
antihistamine 
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antihistamine 
 
 
antidepressant 
 
 
antiseizure 
 
 
antiarrythmic 
 
 
antipsychotic 
 
 
 
diuretic 
  
antipsychotic 
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urinary 
incontinence 
  
analgesic 
       
anxiolysis 
 
 
 
antimalarial 
 
Limitations to drug development from metabolites prepared using CYP450s as biocatalysts on a 
preparative scale have been reported. They arise from difficulties in preparing large volumes of 
enzymes, low stability of the enzymes and the high cost of the cofactors.127,136 However, 
microbial whole cell systems with the membrane bound cofactors have been used in large scale 
biotransformation reactions.136        
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1.4.1 In vitro metabolite generation 
A number of in vitro techniques are used for metabolite generation. Methods include use of 
recombinant CYP450, liver microsomes, and microbial transformation.137,138 Liver microsomes 
are the most commonly used in vitro method for metabolite generation.139 Being sub-cellular 
fractions of the liver, they possess phase I and major phase II enzymes. Either or both of these 
groups of enzymes can be used by addition of the required enzyme cofactors and activators to 
the incubation mixture.140 Liver microsomes are easily prepared by centrifugation of hepatic 
homogenates,131 and can be stored for long periods of time without significant loss of activity. 
However, sample incubation cannot be extended for more than 2h, limiting their use in poorly 
metabolised samples. In addition, they contain only one major class of phase II enzymes, 
uridine-5’-diphosphateglucoronyltransferase.141 
 
Enzymes are unique in the sense that as catalysts, they have been known to be very efficient 
with capability to increase reaction rates 1017 times causing minimal hazard compared to the 
conventional transition metal catalyst.128,142–144 In addition, they are highly chemo-, regio- and 
enantio-selective and hence advantageous in the synthesis of natural, agrochemical and 
pharmaceutical products. They work under mild reaction conditions, such as room temperature 
and neutral or almost neutral pH, resulting in reduced costs that may be incurred, for instance, 
in traditional energy-consuming chemical processes.128,142–144 The CYP450 group of enzymes is 
involved in metabolism of most drugs and is commonly implicated in formation of active 
metabolites.131 Recombinant CYP450 enzymes are therefore used to screen drug candidates 
for metabolite generation and to predict CYP450-based drug-drug interactions. The recombinant 
enzymes are expressed by bioengineered Escherichia coli or insect cells.137 For optimal 
catalytic activity, an electron transport protein, which acts as a redox partner to the CYP450 
enzyme  must either be co-expressed with the CYP450 enzyme or added to the purified 
enzyme.145 A variant of this method is the use of the entire cellular system in E. coli or insect cell 
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as a bioreactor expressing one or several CYP450 enzymes.131 This approach closely models 
the use of microsomes and these membrane preparations are therefore known as 
bactosomes146 when bacterial cells are used, or supersomes131 when insect cells are used.  
 
There are microbial organisms with enzymes able to produce similar metabolites to those found 
in humans. Although not all mammalian metabolites can be obtained utilizing the microbial 
systems, they offer a good option in metabolic studies owing to the relative ease of maintaining 
cultures. Scale-up to produce higher quantities is also easily accomplished. Fungal strains, 
especially Cunninghamella elegans, and bacterial strains like Actinomycetes and S. griseus are 
the most useful.131  
 
1.4.2 Structural characterization of metabolites 
By coupling liquid chromatography with mass spectrometry (LC/MS), it is possible to quantify 
and determine the identity of drugs and metabolites of diverse structures in different biological 
systems with unprecedented speed, sensitivity and specificity. LC/MS, particularly in 
combination with atmospheric pressure ionization (API) i.e. electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI) techniques, can now be used to analyze polar, 
non-volatile, and thermally labile drugs and metabolites. Less polar molecules can be analyzed 
with the recently introduced atmospheric pressure photoionization technique. Advances in 
computer software technology have also greatly facilitated LC/MS data acquisition and 
interpretation. One-dimensional (1D) proton liquid chromatography with nuclear magnetic 
resonance (LC/NMR) often provides information about the structure of metabolites. Various 2D 
NMR experiments can be used to confirm the structure or for identification of more complex 
structures.147–152 
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1.5 Synergistic/matrix antimycobacterial screening and MoA of drugs in combination 
The development of new therapies for bacterial infections has traditionally focused on 
experimental screening for single compounds that inhibit growth. As the identification of active 
new compounds using this approach became less productive, pharmaceutical companies 
diverted their resources to target-based, high-throughput screening campaigns. This approach 
proved to be a lengthy process, with low yields and profits.125 In a study by DiMasi et al.153 68 
drugs obtained from a survey of 10 pharmaceutical firms were analyzed, revealing that it takes 
an average of 14 years and $800 million to bring a single drug to the market. Repurposing or 
repositioning of existing drugs either alone or in combination based on the concept of 
simultaneous targeting of more than one signaling pathway or pathway component has been 
initially attempted and should continue to be explored.86,154,155  
 
Drug combinations are a promising strategy to overcome the compensatory mechanisms and 
unwanted off-target effects that limit the utility of many potential drugs.156 Synergy occurs when 
drugs can interact in ways that enhance or magnify one or more effects, or side-effects, of those 
drugs. Currently, many drugs are being developed in combination to be able to achieve higher 
efficacy. Good examples include artemisinin-based combination therapy (ACT) for the treatment 
of malaria, and antiretroviral drugs (ART) for the management of HIV/Aids,.86,157,158 A number of 
investigations have been carried out to identify synergistic drug combinations and the desired 
activity has been observed in many cases.159–162 In view of the fact that WHO recommends 
combination therapy for TB treatment (Figure 1.14),3 it is almost certainly worth subjecting 
compounds to combination screening at an early stage of drug development in order to select 
the appropriate partners, which can later be used for development of TB drug regimens. 
Although there are no reports to date of the successful development of TB drugs based on their 
properties in combinations in vitro, recent results established that some benzothiazinones in 
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combination with BDQ result in synergistic effects against Mtb, suggesting that this might be a 
useful approach to optimize lead candidates for combination therapy.163,164  
 
 
Figure 1.14 Example of TB combination therapy; BDQ is added to the regimen only in case of MDR-TB 
 
 
Synergistic combinations can result in drugs that show increased potency (equivalent 
therapeutic effects are seen at lower doses) hence minimal toxicity.155 The other type of 
combination is one that leads to enhanced efficacy (whereby the combination has more 
therapeutic benefit than is attained by the single agents at any dose).125 Various combination 
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strategies can be used for synergistic combination studies. Unknown compounds can be tested 
in combination but this attracts a high risk of failure of identifying an efficacious combination. 
Known compounds can also be combined with unknown molecules and this would result in a 
high probability of getting a novel drug combination. The most promising approach would be to 
screen known compounds in combination with known pharmacological profiles hence increasing 
chances of hit discovery.125,165   
 
The synergistic/matrix combination or “checkerboard” assay is currently the most established 
tool for testing drugs in combination in vitro. The measure of interaction between two or more 
drugs is known as fractional inhibitory concentration index (FICI). According to this method, 
synergy is assigned where the FICI < 0.5; a FICI > 4 is considered an antagonistic interaction, 
while any value falling in between indicates no interaction.125,155,166–168 At an early stage of drug 
discovery, high-throughput checkerboard assays have been used successfully in testing millions 
of compounds in chemical libraries giving a good sense of possible drug combinations that can 
be used. Ramon-Garcia et. al.125 identified SPEC (Figure 1.12), an antibiotic with very low 
antimycobacterial activity that synergizes with other drugs such as bromperidol and 
butyrophenone (Figure 1.15) used for treatment of psychosis, as well as other family of drugs 
such as macrolides and azoles.  
 
 
Figure 1.15 Example of drugs synergizing with SPEC 
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Amongst the many properties to consider while choosing partners for drugs, the MoA is of great 
importance.155 The sophisticated nature of Mtb requires a well thought out strategy for choosing 
partners that can be used to clear the infection. A combination of drugs that is active against 
both replicating and non-replicating forms of Mtb should be a good starting point.  
 
Reports indicate that aminoglycosides tend to display synergistic effects when used in 
combination with other drugs such as cell wall synthesis inhibitors.48 Various studies have also 
established that efflux pump inhibitors such as verapamil, reserpine (Figure 1.16) and 
phenothiazines like thioridazine (Figure 1.16) potentiate antimycobacterial activity of anti-TB 
drugs with better results being observed with aminoglycosides.22,23,48,168 These observations can 
probably be attributed to enhanced accumulation of the partner drug in the pair, within the 
mycobacterium cells. Although phenothiazines are reported to inhibit NADH:menaquinone 
oxidoreductase, it is thought that the downstream effect results in efflux pump inhibition hence 
leading to a significant reduction in the minimum inhibitory concentration (MIC99) of the 
partner.113,122,124,155  
 
A good example of the difficulty in predicting positive interactions is provided by the observation 
that INH in combination with CPZ is synergistic, whereas INH and EMB are antagonistic.117,126 
Synergism of drugs observed in vitro may also not necessarily translate to in vivo synergism 
and in fact, in many cases a linear correlation cannot be achieved.169 For example, though 
unrelated to the TB research, lack of correlation between in vitro and in vivo drug synergy is 
evident in the various antiaspergillosis combination drug studies carried out and reported in a 
review authored by Steinbach et al.170 Their review consolidates combination studies carried out 
between 1966 and 2001 - synergy between various drugs is reported in 36% of the in vitro 
studies but is less frequent in vivo at 14%. Lack of correlation may be attributed to the different 
environments within the in vitro and in vivo systems. In an in vivo environment, physiological 
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factors come into play such as absorption, distribution, metabolism, transportation, elimination 
and toxicity of the drugs.171 Consequently, the information generated in an in vitro experiment 
cannot be used to predict synergy outcome in an in vivo environment.  
 
 
Figure 1.16 Examples of efflux pump inhibitors and a phenothiazine 
 
 
1.5.1 In vitro mycobacterial models 
The fast replicating non-pathogenic Msm (mc2155 strain) is an ideal model for the preliminary 
high-throughput screening of thousands of compounds. Studies have shown that it shares some 
genetic similarities with Mtb and can hence be used in the early stages of drug discovery.172,173 It 
provides quick information, which a medicinal chemist can use to select the scaffolds on which 
to focus. This is consistent with reports which have successfully applied Msm for the preliminary 
identification of hit compounds174 as well as promising drug combinations.125  
 
Since its isolation in 1905, Mtb H37Rv has found worldwide application in drug screening and 
biomedical research. Although recent evidence suggests some genetic variation between 
different laboratory isolates,175 most have retained full virulence in vitro, ex vivo and in animal 
models of tuberculosis. Critically, H37Rv is also susceptible to all TB drugs and the strain is 
amenable to genetic manipulation which is key to downstream target identification and 
validation studies.46  
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1.6 Bactericidal and bacteriostatic effect of drugs tested individually and in combination 
It is not only important to establish the MIC99 of a drug tested singly or in combination with other 
partners but also establish whether the drug clears the pathogen (bactericidal) or inhibits its 
growth (bacteriostatic). In case non-replicating Mtb is present, a bacteriostatic agent may not be 
able to clear the mycobacteria hence resulting in a relapse.32 The determination of a bactericidal 
or bacteriostatic effect can be achieved in a 96-well microplate format by plating on Middlebrook 
agar, the contents of the well with the MIC99 concentration of an individual drug or the lowest 
synergistic concentrations of two drugs in combination. The experiment provides information on 
the effect of the drug(s) on the mycobacteria at a given concentration. Nonetheless, it is 
possible to determine a minimal bactericidal concentration (MBC) of a drug through the 
generation of a time-kill curve.32 
                              
1.7 Target identification and MoA determination  
Target identification is an upstream process of identifying reactions or pathways that are critical 
for pathogenesis that is, the disease mechanism, and to characterize proteins/enzymes 
essential for binding of chemical molecules for them to achieve the desired bioactivity. When 
carrying out target identification, it is important to understand the sophisticated metabolic 
pathways of Mtb before exploring probable drug targets. Of importance, is to identify bacterial 
genes that are non-homologous to human genes and are essential for the survival of the 
pathogen, as novel drug targets. Identification of new drug targets has become a major priority 
mainly due to development of resistant strains of Mtb to the old drugs rendering them 
ineffective.15,176–180 It is worth noting that genome-derived, target-based drug discovery 
approaches have had little success in the antibacterial therapeutic area in general. Koul et al.1 
suggest that the essentiality of a target for replication may be a prerequisite but it does not 
ensure its druggability; for many essential targets we are unable to identify specific inhibitors 
with drug-like properties. However, many studies have been carried out to identify targets for 
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various anti-TB drugs using this approach.181 Target identification can be achieved through 
direct biochemical methods, mutant selection or whole genome mutagenesis.182 Potential drug 
targets encoded in microbial genomes include genes involved in translation, transcription, DNA 
replication and repair, outer membrane proteins, permeases, enzymes of intermediary 
metabolism, host-interaction factors, among others.183 
 
On the other hand, MoA determination is a downstream procedure that is carried out to 
establish the processes that are involved in causing chemical compounds to exhibit the desired 
biological effect. This for instance may involve bioconversion of molecules from an inactive form 
to an active form that readily binds to a given target, by enzymes expressed in the organism 
(sections 1.3.3.4 – 1.3.3.6, 1.3.3.9). Spontaneous resistant mutant generation is one of the most 
commonly used methods for determination of the MoA of drugs. The mutations may result in 
alterations of genes in the organism, that encode the enzymes/proteins that are drug targets or 
may be involved in bioconversion of the drug into an active form, hence providing an insight on 
the mode of action of the drug.178,179 In the case where drug development is carried out via SAR 
studies or biotransformation of parent compound(s) with a known target, there is a high 
likelihood that the MoA of the parent will be phenotypically similar to that of its analogue(s) or 
metabolite(s).107 This principle may also be applied to a parent drug in combination with various 
other molecules acting synergistically and with a known MoA, and comparing an unknown MoA 
for analogue(s)/metabolite(s) of similar drug pairs with similar synergy profiles.184,185 Since the 
focus of the work presented in this thesis is mainly on determination of the MoA of selected 
compounds, some techniques used are discussed in detail in the subsequent sections. 
 
1.7.1 Transcriptional responses 
As an adaptation mechanism, organisms respond to changes in the environment by altering the 
level of expression of some genes. These changes involve co-ordinate regulation of sets of 
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genes (regulons) often controlled by single transcriptional regulators that function as genetic 
master switches, committing the bacterium to a major alteration in metabolism.184 Studies 
involving establishment of transcriptional responses in drug treated Mtb and other bacteria, 
have previously been carried out extensively to identify potential MoA of new drugs. In their 
study, Boshoff et al.184 identified transcriptional responses of Mtb to various drugs by generating 
a data set of 430 microarray profiles forming a signature subset of gene clusters, which 
provided an insight into the unknown MoA of several agents such as pyridoacridones and 
phenothiazines. Critical information can also be obtained from transcriptional profiling of both 
crude and purified natural products on both mechanism and detoxification prior to purification 
that can be used to guide the drug discovery process.184  
 
MoA determination can be a daunting task especially during the hit to lead and lead optimization 
stage in drug discovery programs. Murima et al.186 reported a useful approach based on 
transcriptional profiling of a miniaturized gene expression assay for efficient MoA deconvolution 
and discovery chemistry based on a microfluidics platform with integrated fluidic circuits. In their 
sophisticated approach, they are able to achieve a much higher efficiency of a normal 
quantitative polymerase chain reaction (qPCR) by 2 orders magnitude in a single assay using 
nanolitre reaction volumes compared to the standard techniques. 
 
1.7.2 Spontaneous resistant mutant generation 
This technique was developed to identify genes in an organism that undergo an alteration as a 
result of exposure to high concentrations of chemical agents. It starts with a whole-cell screen to 
identify antimycobacterial compounds followed by in vitro selection, isolation and sequencing of 
mutated genes in Mtb that arise from exposure of the mycobacteria to high concentrations of the 
active drug(s). The contribution of each mutation to the resistant phenotype is then confirmed by 
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introducing single point mutations into the parental strain by allelic exchange187 or 
recombineering.179  
 
1.7.3 Biochemical assay 
Drug discovery programs were initially based on whole cell screening of drugs followed by 
determination of activity of the bioactive compounds, on recombineered or purified 
proteins/enzymes for target identification. Medicinal chemists later decided to adopt a different 
strategy and have target identification precede activity determination, a strategy that was 
thought to be more rewarding in pushing forward drugs selected with target specificity.  
Unfortunately, the target-based screening was not a success with only few compounds making 
it through the development pipeline.179 It proved difficult to identify specific inhibitors of essential 
targets, with drug-like properties.188,189 Nevertheless, target-based screening remains an 
important step in drug discovery but should be used as a tool to identify targets for potential lead 
compounds rather than a criterion for elimination of compounds from the development process 
before their whole-cell-activity has been determined.179 A relevant study to the work presented 
here is the one carried out by Weinstein et al.124 who identified the specific target of 
phenothiazines as type II NADH:menaquinone oxidoreductase by screening for activity of the 
compounds on the enzymes expressed in E. coli.   
 
1.8 Repurposing of chlorpromazine (CPZ) - selected hit for proof-of-concept 
CPZ (Figure 1.17), first synthesized in 1950, belongs to a class of compounds known as 
phenothiazines. As earlier mentioned (section 1.3.4), for many years, these compounds had 
been used in the management of psychosis but later it was discovered that the compounds 
exhibited antimycobacterial activity in vitro, ex vivo and in vivo.111,117,122,190 Martins et al., Crowle 
et al.117 and Ordway et al.113 demonstrated that CPZ and thioridazine were capable of inhibiting 
the growth of Mtb that had been phagocytosed by human macrophages at concentrations lower 
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than those used in treatment of pshychosis (0.1 – 3.6mg/L). They attributed this to the drug 
concentrating ability of the macrophages. These studies demonstrated that as 
antimycobacterials, or enhancers of antimycobacterial activity of other antibiotics, there is 
potential of using CPZ or its related compounds in clinical settings. 
 
Further investigations on these compounds were carried out and in the search for a MoA for 
phenothiazines, various studies predicted that the compounds inhibit the electron transport 
pathway,122,123 specifically inhibiting type II NADH:menaquinone oxidoreductase activity which is 
responsible for aerobic respiration.124 The enzyme is a very attractive target due to the fact that 
it in humans, type I NADH dehydrogenase is utilized in the cells, instead, hence reducing 
chances of toxicity.115 Boshoff et al.184 carried out a transcriptional response study of Mtb to 
various drugs including CPZ. Their study indicated that in presence of CPZ, an up-regulation of 
cydA gene that encodes the alternative terminal oxidase (responsible for respiration) in Mtb is 
observed concluding that the gene is an essential target. In a similar approach, Murima et al.186 
were able to demonstrate that phenotypic screens can be used to compare transcriptional 
responses of parent compounds and synthesized derivatives in order to establish the target of 
the latter. This study provides insights into how target identification can be carried out on 
metabolites of CPZ. A negative effect of CPZ on the respiration process in Mtb has also been 
reported to reduce intracellular ATP levels consequently leading to a decline in efflux activity. It 
is therefore not surprising  for the drug to exhibit a 4-fold reduction of efflux pump activity in M. 
avium.190 In addition, CPZ was shown to exhibit synergism in combination with some anti-TB 
drugs 108,117,122,125,126 and this may be attributed to its efflux inhibition capability. This makes CPZ 
a potential partner for combination studies with anti-TB drugs.   
 
The major routes of metabolism of CPZ include hydroxylation, N-oxidation, sulfoxidation, 
demethylation, deamination and conjugation.191 Some studies have indicated that CPZ is 
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metabolized by CYP2D6 to 7-hydroxyCPZ as the main metabolite and the reaction partially 
catalyzed by CYP1A2.192,193 The drug is said to be metabolized to many other products 
however, a few have been identified in rats, man and dog. They include CPZ-N-oxide, CPZ 
sulfoxide, nor-CPZ, nor-CPZ sulfoxide and CPZ-N-S-dioxide (Figure 1.17).194–196 CPZ was 
therefore selected in this study for synergistic combination studies with anti-TB drugs, 
generation of metabolites for further combination assays and establishment of the MoA of the 
metabolites in relation to the parent. 
 
 
Figure 1.17 Reported CPZ metabolites in man, rat and dog 
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1.9 Rationale 
To summarize what has been discussed in this chapter, new drugs are urgently needed 
because TB remains a global health priority. An epidemiological synergy exists with HIV/AIDS 
whereby co-infections represent 15% of the global TB burden and account for almost one 
quarter of HIV/AIDS-associated deaths. Coupled with the emergence of drug-resitant strains of 
Mtb, inadequate anti-TB treatment and limited effectiveness of public health systems, 
particularly in resource-poor countries where the main TB burden lies, it has become a real 
threat to achieve TB control and elimination globally. Drug discovery targeting active 
metabolites is a viable approach. It is very beneficial to have methods in place to allow 
screening of compounds for therapeutically useful biotransformation products for several 
reasons as discussed earlier in this chapter. This approach may lead to drug candidates with 
superior attributes such as improved pharmacodynamics, improved pharmacokinetics, lower 
probability for drug–drug interactions, less variable pharmacokinetics and pharmacodynamics, 
improved overall safety profile and improved physicochemical properties such as solubility. 
Moreover, early screening for active metabolites includes the potential for modifications of an 
entire chemical class to improve overall characteristics, and it also provides for more complete 
patent protection of the parent molecule.  
 
Tracking active metabolites at the drug discovery stage allows for the correct interpretation of 
the pharmacological effect observed in preclinical species in relation to a predicted effect in 
humans. Development of drugs from active metabolites generated from parent drugs is an 
approach that is evident in the various drugs that have been developed and marketed. In 
addition, synergistic/matrix antimycobacterial screening is a powerful tool for drug discovery 
because it involves high-throughput synergy screening (HTSS) of chemical libraries having 
known pharmaceutical properties including thousands that are clinically approved. Hence, the 
incorporation of biological transformation products into synergy screens suggests the potential 
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to develop drug combinations with higher efficacy and superior pharmacokinetic properties. On 
the other hand, determination of the MoA of a drug is important not only to understand how a 
drug exhibits its biological effect, but also to predict chances of development of resistance. This 
forms the basis of this study. 
 
1.10 Hypothesis 
Anti-TB drug combination therapy can be developed from combinations of anti-TB drugs with 
CPZ or its metabolites, the latter exhibiting similar antimycobacterial activity and MoA to the 
parent, but potentially with better pharmacokinetic and safety profiles.  
 
1.11 General objective 
The overall objective was 2-fold:  
a) To generate metabolites of a selected hit compound partner in the ideal combination for 
pharmacological evaluation individually and in combination.  
b) To conduct synergistic/matrix screening of selected hit compounds with known clinically 
used antituberculosis agents in order to identify ideal combination partners. 
 
1.11.1 Specific aims 
i. Selection of compounds to be tested in combination with clinically used anti-TB drugs. 
ii. Selection of parent compounds(s) for metabolite generation based on whole cell 
screening activity. 
iii. Generation of metabolites in vitro via various biotransformation systems. 
iv. Identification, scale up, purification and characterization of metabolites.  
v. Development of combinatorial (matrix) assays for the discovery of synergistic drug 
combinations.  
vi. Pharmacological evaluation of metabolites individually and in combination. 
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vii. Determination of bacteriostatic/bactericidal properties of identified combinations. 
viii. MoA determination of candidate active compounds.  
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CHAPTER 2 
METABOLITE GENERATION, SCALE-UP AND CHARACTERIZATION 
 
2.1 Introduction 
Repurposing or repositioning of existing drugs1–4 represents an appealing approach to 
overcome the limited ability of recent  screening activities to identify viable hit compounds 
against Mycobacterium tuberculosis (Mtb).5 As discussed in the first chapter, one way to 
achieve this is through modification of compounds by biotransformation resulting in active 
metabolites.3,4,6–8 The use of an active metabolite as a drug is attractive in that it may reduce off-
target toxicity: by definition, reducing the number of metabolites that can be generated from the 
applied drug should limit the possibility for unwanted effects which can result from the inhibition 
of essential host functions.3,9 Chlorpromazine (CPZ) was therefore selected for generation of 
metabolites based on earlier reports indicating that it not only exhibits inhibitory effects on Mtb 
but also synergizes with some antituberculosis (anti-TB) drugs.10–15 This chapter addresses the 
first four specific objectives of this study and involves the generation, scale-up, and elucidation 
of CPZ metabolites. 
 
2.2 Metabolite generation from chlorpromazine (CPZ) 
CPZ was initially incubated with several biotransformation systems in order to obtain and 
identify metabolites that could be scaled-up for antimycobacterial testing. Microsomes from 
human and rat liver fractions, recombinant and bioengineered cytochrome P450 (CYP450) 
enzymes, and different actinomycete strains were used in the incubations (section 7.2.1 -7.2.4, 
Chapter 7).  Exposure of CPZ to human liver microsomes (HLM, section 7.2.1, Chapter 7) led to 
generation of oxidation and demethylation products. Seven metabolites identified and fully 
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characterized included CPZ sulfoxide (M1), 7-hydroxyCPZ (M2), CPZ-N-oxide (M3), nor-CPZ 
(M5) and nor-CPZ sulfoxide (M6b) (Scheme 2.1).  
 
 
 
Scheme 2.1 CPZ metabolites generated in HLMs 
 
Similarly, exposure of CPZ to rat liver microsomes (RLM, section 7.2.1, Chapter 7) generated 7 
metabolites (Scheme 2.2). However, in this case, CPZ-N-S-dioxide (M4b) was present in the 
RLM incubation but M2 was not obtained. Full characterization of M4a and M6a was not 
achieved due to failure to obtain the respective standards. Identification of CPZ metabolites in 
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the HLM and RLM incubations in this  study is consistent with previous reports in which the 
same metabolites were identified in the humans, rats and dogs.16–18  
 
 
 
Scheme 2.2 CPZ metabolites generated in RLMs 
 
Exposure of CPZ to four recombinant CYP450 enzymes - 1A2, 2D6, 3A4 and 2C9 - resulted in 
few or no metabolites (section 7.2.2, Chapter 7). CYP1A2 with CPZ led to the formation of M1, 
M2 and M5 (Scheme 2.3). Other CYP450 isoforms have been reported to be responsible for 
CPZ metabolism such as CYP1A1 and CYP2B1.16 
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Scheme 2.3 CPZ metabolites generated in CYP1A2 
 
2.3 Identification and confirmation of CPZ metabolites  
Summarized in Table 2.1 are the metabolites that were obtained in different systems and the 
corresponding retention times are shown on Figure 2.1, Figure 2.2 and Figure 2.3 on the 
extracted ion chromatograms (XIC) of the liquid chromatography/mass spectrometry, 
electrospray ionization (LC/MS, ESI) experiments (section 7.4, Chapter 7). 
 
Initially, tentative elucidation of the structures of CPZ metabolites was carried out by extracting 
the known masses of CPZ metabolites from the total ion chromatograms (TIC) of the HLM, RLM 
and CYP1A2 samples and comparing the fragmentation patterns (Appendices) observed for the 
metabolites in the incubation samples with those of CPZ, reported previously.19  
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Table 2.1: Summary: comparing LC/MS retention times of CPZ metabolites generated through biotransformation versus standards or 
synthesized molecules 
 MH
+ m/z  HLM  RLM  CYP2D6  CYP3A4  CYP1A2  CYP2C9  CYP21B3 Actinomycetes Synthesized/purchased  
metabolite 
Retention time - Extracted Ion Chromatogram (XIC) 
Oxidation 335  M1  5.26  5.17  5.19  5.59  5.21  5.25  -  -  5.20 
M2  6.00  -  -  -  5.95  -  -  -  6.05 
M3  6.92  6.90  -  -  -  -  -  -  6.98 
Di-oxidation  351  M4a  5.47  5.41  -  -  -  -  -  -  NS 
 M4b  - 6.06  -  -  -  -  -  -  5.98 
Demethylation  305  M5  6.66  6.63  -  -  6.57  -  -  -  6.61 
Demethylation + 
oxidation  
321  M6a  5.92  5.87  -  -  -  -  -  -  NS 
M6b  5.18  5.12  -  -  -  -  -  -  5.26 
 
NS: Not synthesized; - no metabolite detected 
 
Many metabolites tend to ionize in the same mode as the parent drugs. For instance, the structure of the demethylated product (M5), 
that is, nor-CPZ, was confirmed by comparing the reported fragmentation pattern of CPZ (MH+ peak 319, 274, 246, 214) with that 
obtained for M5 (MH+ peak 305, 274, 246, 214) which clearly indicated that the molecular mass (m/z) of the metabolite was less by 
14 mass units due to the absence of one methyl group on the chain. However, the subsequent fragments retained the CPZ 
fragmentation pattern. All the other metabolites (M1, M2, M3, M4a, M4b, M6a, M6b) observed in the biotransformation samples were 
identified in the same manner (Appendices).  
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Figure 2.1 XIC of the various metabolites generated by HLM, eluting at different retention times 
 
 
 
Figure 2.2 XIC of the various metabolites generated by RLM, eluting at different retention times 
 
Relative to other biotransformation systems, microsomal incubations generated most of the 
CPZ metabolites (Scheme 2.1, Table 2.1). Microsomes are derived from the liver sub-
cellular fractions from the respective organism (i.e. human and rat). This observation is not 
surprising since the liver is the main organ in which xenobiotic metabolism takes place due 
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to presence of most of the metabolizing enzymes which include CYP450s, esterases, flavin 
monooxygenase, alcohol dehydrogenase, and aldehyde dehydrogenase among many 
others. 6,7,20  
 
 
 
Figure 2.3 XIC of the various metabolites generated by CYP1A2, eluting at different retention times 
 
Although CYP1A2 led to the formation of M1, M2 and M5, previous studies have established 
that 7-hydroxy metabolites are predominantly formed from phenothiazines via catalysis by 
CPY2D6.21,22 On the other hand, CYP1A2 is said to be responsible for metabolism of this 
class of compounds but to a lesser extent.23 This is contrary to another study which reported 
that demethylation and sulfoxidation of CPZ is favored by CYP1A2 isoform.21,23,24 However, 
in the results presented here, CYP2D6 only generated CPZ sulfoxide (M1) which was also 
formed by catalysis of CPZ by CYP3A4 and CYP2C9. Despite the fact that metabolism of 
several drugs has been demonstrated using CYP21B325 and actinomycetes,26 these 
systems did not yield metabolites of CPZ in this study (Table 2.1). Failure to obtain 
metabolites in the latter systems can be partly explained by the fact that optimization of the 
incubations was not carried out. On the other hand, the conditions necessary for expression 
of the recombinant CYP1A2 in Escherichia coli and incubation of CPZ with the enzyme were 
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optimized leading to generation of three metabolites (Table 2.2). This is not surprising 
because the conditions achieved here for CYP1A2, have been applied in other CYP450 
studies.27 Owing to constraints of time, the same could not be achieved with other systems.  
 
Table 2.2: Conditions optimized for growth of E. coli, expression of CYP1A2 and incubation 
of CPZ  
Parameters Optimal conditions 
Induction of CYP450 expression (OD600) 0.8 - 1 
Duration of growth after induction (h) 48 
Growth temperature (oC) 30 
Shaking speed ( x g) 180 - 200 
Concentration of drug (µM) 100 
Optimal pH of incubation of the drug  7.4 
Drug incubation time (h) 48 
 
The purpose of optimizing the conditions for generating metabolites of CPZ with CYP1A2 
was to scale-up metabolite yield. However, chemical synthesis of the metabolites became 
the most viable route due to the large quantities of metabolites required for antimycobacterial 
screening. Nevertheless, optimizing the conditions given above is an important step for 
future development of the findings in this study. 7-HydroxyCPZ (M2) could in future be 
obtained through large scale whole cell biotransformation of CPZ via CYP1A2 catalysis, 
since the metabolite could not be synthesized chemically. It is also worth pointing out that 
identification of specific enzyme(s) responsible for metabolism of a drug is important in drug 
discovery programs for the purpose of understanding the pharmacokinetic profiles of a drug, 
which could potentially interact enzymatically with other drugs, chemicals or food in an in 
vivo environment leading to a positive or a negative outcome.7 
 
2.4. Scale-up of CPZ metabolites 
2.4.1 7-HydroxyCPZ (M2) 
7-HydroxyCPZ (M2) was purchased and used to identify one of the metabolites by 
comparing the retention times obtained from LC/MS analysis. The retention time of the 
CHAPTER 2 
66 
 
standard corresponded to the M2 metabolite in the HLM incubation of CPZ (section 7.5.1, 
Chapter 7, Figure 7.1). 
      
2.4.2 Synthesis of other CPZ metabolites 
CPZ-N-oxide (M3), CPZ sulfoxide (M1), nor-CPZ (M5), nor-CPZ sulfoxide (M6b) and CPZ-N-
S-dioxide (M4b) were synthesized via a non-classical Polonovski reaction (Scheme 2.4, 
section 7.5.2 – 7.5.6, Chapter 7).4  
 
 
 
Scheme 2.4 Synthesis of CPZ metabolites using Polonovski scheme 
 
The central feature of this reaction is that it involves the conversion of the amine to the 
corresponding N-oxide.28 Depending on the structure of the substrate and the acid anhydride 
or other activating reagent employed, iminium ion formation can occur through loss of an α-
hydrogen, or through fragmentation of a Cα-carbon bond.28,29 meta-Chloroperbenzoic acid 
(m-CPBA) is more selective and easier to handle than other oxidizing agents.29 The N-oxide 
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formed then reacts with an iron(II) sulfate heptahydrate, which induces elimination and 
ultimately affords an iminium ion intermediate that reacts further to yield the N-demethylated 
product.28,29 Singh et al.29  employed a modified form of the scheme to synthesize the N-
demethylated metabolite of the neuroleptic drug, cyamemazine.  
 
Likewise, in the presence of sodium hydroxide (NaOH), m-CPBA in dichloromethane 
(CH2Cl2) was used in this study to oxidize CPZ to form the N-oxide (M3) and the sulfoxide 
(M1). CPZ-N-oxide (M3) was dissolved in methanol (MeOH), the solution was cooled, 
followed by an addition of a solution of ferrous sulfate (FeSO4) in MeOH. The residue was 
dissolved in ethylenediaminetetraacetic acid (EDTA) solution at pH 10 adjusted using 
ammonia (NH3) solution. Nor-CPZ (M5) was then purified using column chromatography.  
 
Further oxidation was carried out on nor-CPZ (M5) and CPZ sulfoxide (M1) using m-CPBA 
as described for the N-oxide (M3) to form nor-CPZ sulfoxide (M6b) and CPZ-N-S-dioxide 
(M4b) respectively. Interestingly, deviating from the recommended time (4h) of the first step 
reaction,29 to 24h, led to the formation of the CPZ-N-oxide (M3) and not the CPZ sulfoxide 
(M1) hence maximizing on the amount of N-oxide (M3) that was required for the formation of 
the demethylated product (M5) and the N-S-dioxide (M4b) (Scheme 2.4). 
 
All the synthesized compounds were identified using Nuclear Magnetic Resonance (NMR) 
and LC/MS (section 7.5, Chapter 7, Appendices). The retention times of the metabolites 
generated in the microsomal incubations from CPZ were comparable to those observed from 
the synthesized compounds, thereby confirming the identity and structures of the products in 
the incubation samples (Table 2.1, section 7.5.2 – 7.5.6, Chapter 7).  
 
2.5. Summary discussion 
Generation and scale-up of CPZ metabolites was successfully carried out in this study. 
Although many biotransformation systems did not generate CPZ metabolites, the major 
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biotransformation products of the phenothiazine were identified in the microsomal 
incubations, consistent with what has been reported before.16–18,21,23,24,30,31 Optimization of 
CYP1A2 incubations of CPZ was also an important exercise that may guide further work on 
generation of the hydroxyl metabolite (M2) that can potentially be of use for further structure 
relationship studies (SAR) of this class of compounds for tuberculosis (TB) drug discovery. 
Synthesis of the metabolites as a way of scaling-up, was also achieved through the 
Polonovski scheme4,28,29 resulting in substantial yields of the major metabolites, for 
antimycobacterial screening experiments. 
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CHAPTER 3 
SYNERGISTIC/MATRIX ANTIMYCOBACTERIAL COMBINATION SCREENING 
 
 
3.1 Introduction 
Examples from unrelated fields such as cancer drug discovery suggest the potential for 
simultaneously targeting more than one pathway or pathway component1 as part of 
fractional combination therapies designed to achieve synergies in drug action. Drug synergy 
occurs when the interaction between two or more compounds enhances the individual 
activities of each. There are a number of examples of drugs that have been developed in 
combinations designed to increase efficacy while limiting the emergence of drug resistance 
(discussed in Chapter 1). To accentuate what was mentioned earlier in the first chapter, it is 
a worthy course to include combination screening in the early stages of drug development in 
order to identify potential partners for novel antituberculosis (anti-TB) drug regimens, given 
that combination therapy is standard for tuberculosis (TB).2 The fifth and sixth specific 
objectives of this study are discussed in this chapter in which the use of checkerboard 
assays - which are most commonly applied to test drug combinations in vitro, and provide a 
measure of the nature of the interaction between two drugs in the form of a fractional 
inhibitory concentration index (FICI) - is demonstrated.3–5  
 
3.2 In vitro assays against Mycobacterium smegmatis (Msm) 
3.2.1 Microplate Alamar Blue Assay (MABA) for determination of minimum inhibitory 
concentrations (MIC99) of chlorpromazine (CPZ) or its metabolites 
The MIC99 values determined (section 7.3.1, Chapter 7) for CPZ and its metabolites are 
shown in Table 3.1. The antimycobacterial activity of CPZ and its metabolites against Msm 
were generally low. Interestingly, the activity of the CPZ metabolites, 7-hydroxyCPZ (M2) 
and nor-CPZ (M5) were comparable to that of CPZ, confirming the two as the active 
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metabolites of CPZ.6 This is in agreement with studies where hydroxylation and 
demethylation of various drugs through biotransformation have led to generation of active 
metabolites (section 1.4, Chapter 1).7–9  CPZ-N-oxide (M3) has been reported to revert to 
CPZ in solution and this may contribute to some of its activity.10 In some instances, 
heteroatom oxidation (N, S, and P) has led to active metabolites.7 However, in this study, 
oxidation of S and N atoms of CPZ (M1, M4b, M6b) resulted in metabolites with weak 
antimycobacterial activity. 
 
Table 3.1: MIC99 of CPZ or its metabolites against Msm 
Drugs/Compound  MIC99 (µM) in Msm 
CPZ  117.26  
CPZ  sulfoxide (M1)  >1990.89  
7-hydroxyCPZ (M2)  124.44+6.01 
CPZ-N-oxide (M3)  995.43  
nor-CPZ (M5)  136.70  
nor-CPZ sulfoxide (M6b)  >2077.89  
CPZ-N-S-dioxide (M4b)  >1900.10  
 
 
3.2.2 Synergistic/matrix screening 
Table 3.2 and Table 3.3 summarize the MIC99 values determined for the individual 
compounds, the lowest MIC99 achieved in the various combinations of CPZ and its 
metabolites with known anti-TB drugs and the FICI (section 7.3.2, Chapter 7). According to 
the standard definition, synergy is assigned where FICI < 0.5; an FICI >4 is antagonistic 
while any value falling in between indicates no interaction.3,5,6,11,12 Generally, combinations of 
CPZ with known anti-TB drugs exhibited improved activity against Msm. The combination of 
CPZ with spectinomycin (SPEC) or 25-O-desacetylrifampicin (25-O-desacetylRIF) resulted 
in definite synergy (FICI 0.31, 0.50 respectively, Table 3.2).6,12 It is worth mentioning that 25-
O-DesacetylRIF, reported to be the active metabolite of rifampicin (RIF),9,13 was included in 
the synergistic matrix screening for further investigation of the contribution of drug 
metabolites to the biological activity.  
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Table 3.2: FICI of CPZ or its metabolites in combination with antimycobacterial drugs against 
Msm 
Drugs/Compound  MIC99 (µM), singly MIC99 (µM) in combination MIC99 fold 
reduction 
FIC FICI 
RIF 
25-O-DesacetylRIF 
1.26+0.3 0.63+2  0.500 
1.00 
2.66+2.17 1.33+1.08  0.500 
RIF 
CPZ 
2.53+0.54 0.32 + 0.19 8 0.126 
0.63 
117.27+6.01 58.62+10.84  0.500 
25-O-DesacetylRIF 
CPZ 
5.33+1.59 1.33+0.49 4 0.250 
0.50 
117.27 29.32+7.36  0.250 
EMB 
CPZ 
0.76+0.12 
NC 
117.27+6.01 
KANA 
CPZ 
7.16+1.1 3.57+0.54 2 0.500 
1.00 
117.27+7.36 58.62+5.52  0.500 
STRP 
CPZ 
0.07+0.07 0.02 3.5 0.286 
0.79 
58.62+15.19 29.32+8  0.500 
SPEC 
CPZ 
84.12+24.05 5.25 16 0.062 
0.31 
117.27 29.32  0.250 
BDQ 
CPZ 
0.05+0.02 0.01 5 0.200 
0.70 
117.27 58.62  0.500 
Nalidixic acid* 
CPZ 
1435.28 358.81 4 0.250 
 
117.27 58.62  0.500 
Ciprofloxacin* 
CPZ 
0.63 0.30 2 0.476 
0.73 
117.27 29.32  0.250 
Levofloxacin 
CPZ 
0.58 
NC 
117.27 
RIF 
7-hydroxyCPZ (M2) 
2.53+0.6 0.32+0.15 8 0.126 
0.63 
62.21+6.01 31.12+3  0.500 
25-O-DesacetylRIF 
7-hydroxyCPZ (M2) 
1.33+2.41 0.33+0.6 4 0.248 
0.75 
124.44+12.03 62.21+6.01  0.500 
EMB 
7-hydroxyCPZ (M2) 
0.76+0.12 
IAE 
124.44+12.03 
KANA 
7-hydroxyCPZ (M2) 
3.57 0.89 4 0.249 
0.50 
124.44 31.12  0.250 
STRP 
7-hydroxyCPZ (M2) 
0.07+0.14 0.02+0.04 3.5 0.286 
0.79 
124.44+12.03 62.21+10.33  0.500 
SPEC 
7-hydroxyCPZ (M2) 
84.12+24.05 5.25+10.53 16 0.062 
0.19 
124.44+15.91 15.56+2.47  0.125 
CPZ 
7-hydroxyCPZ (M2) 
117.27+12.03 29.32+6.01  0.250 
0.75 
124.44+12.03 62.21+6.01  0.500 
RIF 
CPZ-N-oxide (M3) 
1.26+0.72 0.63+0.18 2 0.500 
1.00 
995.43 497.73  0.500 
25-O-DesacetylRIF 
CPZ-N-oxide (M3) 
2.66+2.41 0.67+0.38 4 0.252 
0.75 
995.43 497.73  0.500 
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EMB  
CPZ-N-oxide (M3) 
0.76 
IAE 
995.43 
KANA  
CPZ-N-oxide (M3) 
1.79+1.03 0.89 2 0.497 
1.00 
995.43 497.73  0.500 
STRP  
CPZ-N-oxide (M3) 
0.29 0.07 4 0.241 
0.74 
995.43 497.73  0.500 
SPEC  
CPZ-N-oxide (M3) 
168.22+24.05 84.12 2 0.500 
0.63 
995.43 124.44+71.84  0.125 
CPZ 
CPZ-N-oxide (M3) 
117.27 58.62  0.500 
0.75 
995.43 248.85  0.250 
RIF 
nor-CPZ (M5) 
1.26+0.6 0.32 4 0.254 
0.50 
136.70 34.18+6.01  0.250 
25-O-DesacetylRIF 
nor-CPZ (M5) 
2.66 0.67+0.15 4 0.252 
0.50 
136.70 34.18+6.01  0.250 
EMB 
nor-CPZ (M5) 
1.51+1.58 
IAE 
63.33+12.03 
KANA 
nor-CPZ (M5) 
3.57+1.21 0.89+0.23 4 0.249 
0.50 
136.70+12 34.18+6.01  0.250 
STRP 
nor-CPZ (M5) 
0.29 0.07+0.01 4 0.241 
0.49 
136.70+0 34.18+6.01  0.250 
SPEC 
nor-CPZ (M5) 
84.12 5.25+4 16 0.062 
0.31 
136.70+31.82 34.18+4.51  0.250 
CPZ 
nor-CPZ (M5) 
117.27 29.32  0.250 
0.75 
136.70 68.33+6.01  0.500 
 
IAE – Inconsistent antagonistic effect; NC – No Change; *poor solubility - single experiment  
 
Like the parent (CPZ), 7-hydroxyCPZ (M2) resulted in enhanced antimycobacterial activity in 
combination with anti-TB drugs (Table 3.2). For instance, synergistic interactions were 
observed for kanamycin (KANA) and SPEC (FICI 0.50, 0.19 respectively). Nor-CPZ (M5), 
just like CPZ and M2, potentiated the antimycobacterial activity of some of the anti-TB drugs 
selected for this study against Msm. Synergy was observed for combinations of M2 with RIF, 
25-O-desacetylRIF, KANA, streptomycin (STRP) or SPEC (FICI < 0.50, Table 3.2).6,12 
Notably, CPZ and its metabolites reproducibly reduced the MIC99 of the antibiotics at least by 
2-fold with the highest reduction observed with SPEC at 16-fold followed by RIF at 8-fold. 
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Table 3.3: Inactive metabolites of CPZ in combination with anti-TB drugs, against Msm 
Drugs/Compound  MIC99 (µM), singly MIC99 (µM) in combination MIC99  fold reduction 
RIF 
CPZ sulfoxide (M1) 
2.53+0.74 
NC 
>1990.89 
EMB 
CPZ sulfoxide (M1) 
0.76 
IAE 
>1990.89 
KANA 
CPZ sulfoxide (M1) 
1.79+1.1 0.89 
2-fold 
>1990.89 1990.89 
STRP 
CPZ sulfoxide (M1) 
0.29 0.14 
2-fold 
>1990.89 62.21+25.6 
SPEC 
CPZ sulfoxide (M1) 
168.22+48 10.52+3.1 
16-fold 
>1990.89 1990.89 
RIF 
CPZ-N-S-dioxide (M4b) 
2.53+1.46 
NC 
>1900.10 
EMB 
CPZ-N-S-dioxide (M4b) 
0.76+0.15 
IAE 
>1900.10 
KANA 
CPZ-N-S-dioxide (M4b) 
1.76 0.89 
2-fold 
>1900.10 475.03+44.1 
STRP 
CPZ-N-S-dioxide (M4b) 
0.29 0.14 
2-fold 
>1900.10 237.50+58.93 
SPEC 
CPZ-N-S-dioxide (M4b) 
84.12 42.05 
2-fold 
>1900.10 1900.10 
RIF 
nor-CPZ sulfoxide (M6b) 
1.26+0.3 
NC 
>2077.89 
EMB  
nor-CPZ sulfoxide (M6b) 
0.76+0.12 
IAE 
>2077.89 
KANA  
nor-CPZ sulfoxide (M6b) 
1.76+0.6 
NC 
>2077.89 
STRP  
nor-CPZ sulfoxide (M6b) 
0.14+0.05 0.07+0.07 
2-fold 
>2077.89 519.48+37.6 
SPEC  
nor-CPZ sulfoxide (M6b) 
84.12 21.04+5.43 
4-fold 
>2077.89 64.92+14.74 
 
IAE – Inconsistent antagonistic effect; NC – No Change 
 
CPZ sulfoxide (M1), CPZ-N-S-dioxide (M4b) and nor-CPZ sulfoxide (M6b) were all inactive. 
Thus, the respective FICIs could not be calculated for the various combinations involving 
these metabolites. Interestingly, they were nevertheless able to augment the 
antimycobacterial activity of some of the anti-TB drugs used in this study. Similar to CPZ and 
its active metabolites, M1 and M6b reduced the MIC99 of SPEC 16-fold and 4-fold 
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respectively (Table 3.3). A 2-fold drop in MIC99 was observed for some of other combinations 
(Table 3.3).6,12  
 
It should be noted that all combinations of CPZ and its metabolites with ethambutol (EMB) 
against Msm resulted in inconsistent antagonistic interactions whereas, on its own, the MIC99 
value of EMB was rather consistent. Such effects with EMB in combination with other drugs 
have been reported before.14,15 Similarly, combinations of isoniazid (INH) with CPZ and its 
metabolites were also carried out but INH had no activity against Msm and consequently a 
synergistic effect was not observed. The susceptibility of Msm to INH is reported to be very 
low (100 times less than in Mtb) hence the observed results.16,17 
 
3.3 In vitro assays against Mtb 
3.3.1 MABA for determination of MIC99 of CPZ or its metabolites 
MIC99 values determined (section 7.3.1, Chapter 7) for CPZ and its metabolites against Mtb 
are shown in Table 3.4. Similar to the observations made against Msm, the 
antimycobacterial activity of CPZ and its metabolites against Mtb was also generally weak. 
The activities of CPZ metabolites, 7-hydroxyCPZ (M2) and nor-CPZ (M5), were also 
comparable to that of CPZ, again confirming the two as the active metabolites. The low 
activity observed against Msm was also observed against Mtb for M1, M3, M4b and M6b at 
the highest concentrations tested.  
 
Table 3.4: MIC99 of CPZ or its metabolites against Mtb 
Drugs/Compound  MIC99 (µM) in Mtb 
CPZ  58.63 
CPZ  sulfoxide (M1)  >1990.89 
7-hydroxyCPZ (M2)  62.21 
CPZ-N-oxide (M3)  497.73+10.71 
nor-CPZ (M5)  68.34 
nor-CPZ sulfoxide (M6b)  >2077.89 
CPZ-N-S-dioxide (M4b)  >1900.10 
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3.3.2 Synergistic/matrix screening 
Table 3.5 and Table 3.6 summarize the MIC99 values determined for the individual 
compounds, the lowest MIC99 values achieved in the various combinations of CPZ and its 
metabolites with known anti-TB drugs and the FICI against Mtb (section 7.3.2, Chapter 7).  
 
Improved activity was observed in combinations of CPZ or the metabolites with anti-TB 
drugs against Mtb. In fact, interactions obtained for the various pairs tested against Mtb 
resulted in greater synergy compared to those tested against Msm. CPZ in combination with 
RIF and its metabolite, 25-O-desacetylRIF, SPEC, INH, bedaquiline (BDQ) or nalidixic acid 
yielded synergism with FICI < 0.5 and a 10 to 500-fold reduction of MIC99 value of the 
antibiotic (Table 3.5). This is in agreement with a previous study where CPZ was reported to 
augment activity of INH, STRP, pyrazinamide (PZA), RIF, rifabutin and penicillin against Mtb 
and M. avium in normal human macrophages, but this was not the case with EMB.14 
Combinations of M2 with 25-O-desacetlylRIF, BDQ and SPEC exhibited the highest 
synergistic interaction with FICI of 0.36, 0.25 and 0.13 respectively, followed by RIF, INH 
and STRP (FICI 0.50) against Mtb. Nor-CPZ (M5) in combination with SPEC and BDQ 
exhibited synergistic interactions with FICI values of 0.19 and 0.31 respectively (Table 3.5). 
In addition, M5 in combination with RIF, 25-O-desacetylRIF, and KANA resulted in 
synergism at FICI of 0.5 (Table 3.5). In addition to the synergistic interactions, at least a 4-
fold reduction was observed in MIC99 values of most of the antibiotics combined with CPZ 
and its active metabolites. The highest reduction recorded was for combinations of CPZ with 
SPEC or BDQ at 128- and 508-fold respectively (Table 3.5). 
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Table 3.5: FICI of CPZ or its metabolites in combination with anti-TB drugs, against Mtb 
Drugs/Compound  MIC99 (µM), singly MIC99 (µM) in combination MIC99 fold 
reduction 
FIC FICI 
RIF 
CPZ 
0.0032+0.04 0.00037 8.6 0.116 
0.37 
58.63 14.66  0.250 
25-O-DesacetylRIF 
CPZ 
0.0017 0.00038 4.5 0.224 
0.47 
29.32+6.01 7.32+1.51  0.250 
Ehthambutol 
CPZ 
6.02+3 
NC 
58.63 
INH 
CPZ 
0.38 0.094 4 0.247 
0.50 
58.63 14.66  0.250 
KANA 
CPZ 
7.16+3 3.57+0.1 2 0.499 
1.00 
58.63 29.32+6.01  0.500 
STRP 
CPZ 
1.15+0.2 0.14 8 0.122 
0.62 
58.63 29.32  0.500 
SPEC 
CPZ 
168.22+97.14 1.31+1 128.4 0.0078 
0.26 
29.32+6.01 7.32+4.51  0.250 
BDQ 
CPZ 
3.00+0.64 0.0059 508.5 0.002 
0.25 
29.32+6.01 7.32+1.51  0.250 
Nalidixic acid* 
CPZ 
1435.28 179.41 8 0.125 
0.25 
58.63 7.32  0.125 
Ciprofloxacin* 
CPZ 
2.50 1.27 2 0.508 
0.76 
58.63 14.66  0.250 
Levofloxacin 
CPZ 
2.30+3.4 
NC 
58.63 
RIF 
7-hydroxyCPZ (M2) 
0.0063 0.0016 4 0.254 
0.50 
62.21 15.56+1.12  0.250 
25-O-DesacetylRIF 
7-hydroxyCPZ (M2) 
0.0016 0.00037 4 0.231 
0.36 
31.12+18 3.88+2.24  0.125 
INH  
7-hydroxyCPZ (M2) 
0.73 0.19 4 0.260 
0.51 
62.21 15.56  0.250 
KANA 
7-hydroxyCPZ (M2) 
3.57 
NC 
62.21 
STRP 
7-hydroxyCPZ (M2) 
1.15+0.24 0.29+0.06 4 0.252 
0.50 
62.21 15.56  0.250 
SPEC 
7-hydroxyCPZ (M2) 
336.47 21.04 16 0.063 
0.13 
124.44+14.74 7.76  0.063 
BDQ 
7-hydroxyCPZ (M2) 
0.76 0.094+0.03 8 0.124 
0.25 
62.21 7.76  0.125 
Nalidixic acid* 
7-hydroxyCPZ (M2) 
179.41 89.69 2 0.500 
0.63 
62.21 7.76  0.125 
RIF 
CPZ-N-oxide (M3) 
0.0063 0.0016 4 0.254 
0.75 
497.73 248.85+71.83  0.500 
SPEC  336.47 NC 
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CPZ-N-oxide (M3) 497.73 
BDQ 
CPZ-N-oxide (M3) 
0.76+0.22 0.047+0.03 16 0.062 
0.31 
497.73 124.44+35.92  0.250 
RIF 
nor-CPZ (M5) 
0.0063 0.0016 4 0.254 
0.50 
68.34 17.09  0.250 
25-O-DesacetylRIF 
nor-CPZ (M5) 
0.0067 0.0017 4 0.254 
0.50 
68.34 17.09  0.250 
INH 
nor-CPZ (M5) 
0.38 0.095+0.05 4 0.250 
0.50 
68.34+39.47 17.09+4.93  0.250 
KANA 
nor-CPZ (M5) 
3.57 0.89 4 0.250 
0.50 
136.70+39.47 34.18  0.250 
STRP 
nor-CPZ (M5) 
0.57+0.24 0.036+0.04 16 0.063 
0.56 
68.34 34.18  0.500 
SPEC 
nor-CPZ (M5) 
336.47 21.04 16 0.063 
0.19 
68.34 8.53  0.125 
BDQ 
nor-CPZ (M5) 
1.49 0.094 16 0.063 
0.31 
68.34 17.09  0.250 
 
NC – No Change; *poor solubility - single experiment 
 
Combinations of anti-TB drugs with the inactive CPZ metabolites resulted in improved 
antimycobacterial activity. CPZ sulfoxide (M1) reduced the MIC99 value of RIF, BDQ and 
SPEC by 17-, 4- and 4-fold respectively (Table 3.6). CPZ-N-S-dioxide (M4b) reduced the 
MIC99 of BDQ by 16-fold while nor-CPZ sulfoxide (M6b) delivered a reduction in MIC99 value 
of RIF, BDQ and SPEC by 8-, 33- and 4-fold respectively (Table 3.6). This suggests that, in 
addition to antimycobacterial effect, CPZ and its metabolites exhibit additional mechanism(s) 
of action (MoA) that result in potentiation of the activity of other drugs.18–20  
 
Table 3.6: Inactive metabolites of CPZ in combination with anti-TB drugs against Mtb 
Drugs/Compound  MIC99 (µM), singly MIC99 (µM) in combination MIC99  fold reduction 
RIF 
CPZ sulfoxide (M1) 
0.0063                                                                            0.00037
17-fold 
>1990.89 1990.89 
SPEC 
CPZ sulfoxide (M1) 
168.22+48.56 42.05+12.14 
4-fold 
>1990.89 497.73 
BDQ 
CPZ sulfoxide (M1) 
0.76 0.18+0.1 
4-fold 
>1990.89 497.73 
RIF 
CPZ-N-S-dioxide (M4b) 
0.013 
NC 
>1900.10 
SPEC 336.47 168.22 2-fold 
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CPZ-N-S-dioxide (M4b) >1900.10 950.04  
BDQ 
CPZ-N-S-dioxide (M4b) 
0.76 0.047+0.03 
16-fold 
>1900.10 1900.10 
RIF 
nor-CPZ sulfoxide (M6b) 
0.0063 0.00083 
8-fold 
>2077.89 2077.89 
SPEC  
nor-CPZ sulfoxide (M6b) 
336.47 84.12+12.14 
4-fold 
>2077.89 519.48 
BDQ  
nor-CPZ sulfoxide (M6b) 
0.76 0.023+0.01 
33-fold 
>2077.89 2077.89 
 
NC – No Change 
 
3.4 Summary discussion 
It should be noted that, before the commencement of this PhD project, combinations of CPZ 
metabolites with anti-TB drugs against Mtb had not been previously reported. The first 
publications in this area arose from this work.6,12 Furthermore, the results obtained here 
have established that the checkerboard assay is a powerful tool for measuring interactions 
between pairs of drugs, as previously reported by others.3–5,11,21–23  
 
In summary, synergism was observed in more of the combinations against Mtb compared to 
Msm. This may be explained by the fact that Msm has inherent resistance due to high 
metabolic capacity, as an adaptation strategy to the harsh environment that it exists in which 
is basically in soil, water and plants.24 This is, however, not the case with Mtb that survives in 
an in vivo host environment and hence having less adaptation physiological features 
compared to Msm. 
 
Against Msm and Mtb, SPEC exhibited the best synergistic interactions with CPZ and its 
metabolites. This is not unexpected: combinations of SPEC and other drugs were previously 
reported to be synergistic, though the precise mechanism underlying the ability of SPEC to 
potentiate multiple different drug classes remains unclear despite the elucidation of its target 
in this project (discussed in Chapter 5).5 In general, combinations of CPZ and its metabolites 
with aminoglycosides resulted in positive interactions, prompting questions on whether or not 
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the interactions have any correlations with their MoA. It has been reported that 
aminoglycosides, which are known to target ribosomes leading to inhibition of protein 
synthesis in the mycobacteria, tend to have synergistic effects with other drugs such as cell 
wall synthesis inhibitors, resulting in increased accumulation of the drug within the 
mycobacterial cell.25 It has been reported that the MoA of CPZ is most likely associated with 
inhibition of type II NADH:menaquinone oxidoreductase activity which is responsible for 
aerobic respiration. It is also presumed that down the cascade of the cellular activities 
related to respiration, inhibition of the oxidoreductase may lead to inhibition of the electron 
transport pathway.18,26 Subsequently, in a combination of CPZ or the metabolites with 
aminoglycosides, higher accumulation of the latter may be achieved in the mycobacterial cell 
leading to improved activity for this class of compounds. The MoA described here may also 
be used to explain synergistic interactions demonstrated for combinations of CPZ or its 
metabolites with the other classes of drugs.  
 
Of importance also is to note that the inactive metabolites of CPZ which are also reported to 
be inactive in psychosis do potentiate the activity of the antibiotics.27,28 These metabolites 
may stand a better chance of not exhibiting the undesired antipsychotic effect hence proving 
to be better candidates for selection for an anti-TB combination therapy. 
 
Finally, an observation was made whereby improved antimycobacterial activity was not 
achieved in similar combinations with fluoroquinolones, except for nalidixic acid against Mtb; 
in this case, however, the poor solubility of nalidixic acid is associated with inconsistent 
MIC99 values.  
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CHAPTER 4 
DETERMINATION OF THE MECHANISM OF ACTION (MoA) OF 
CHLORPROMAZINE (CPZ) & ITS METABOLITES, AND COMBINATIONS WITH 
ANTITUBERCULOSIS (ANTI-TB) DRUGS 
 
 
4.1 Introduction 
Determination of the MoA of a drug is normally carried out when its biological activity has 
been established as discussed in section 1.7, Chapter 1. Drug susceptibility of the 
mycobacteria is determined by multiple factors, which include growth state, the inherent 
impermeability of the mycobacterial cell wall, and the ability of a drug to interact with a 
target.1 Critically, the recent identification of some “promiscuous” membrane targets, 
including QcrB, suggests that the respiratory electron transport chain is an essential pathway 
that drug molecules can be designed to target.1–3 Interestingly, Mtb is able to survive in 
aerobic and anaerobic environments by switching its respiratory functions from the former 
state to the latter and vice versa.3 This chapter explores various possibilities with regard to 
the MoA of chlorpromazine (CPZ) metabolites and the interactions observed in the 
combination assays (Chapter 3) in relation to the reported target of CPZ, type II 
NADH:menaquinone oxidoreductase. The dehydrogenase plays the role of initiating the 
branched aerobic respiratory chain that terminates in a cytochrome bd and a cytochrome 
aa3 complexes encoded by cydABCD and ctaBCDE respectively.1,3–5 The type II NADH 
dehydrogenase in Mtb is an important antimicrobial target because in humans, the 
mitochondria use only type I NADH dehydrogenase.3 This would therefore reduce chances 
of toxicity. The chapter therefore addresses the seventh and eighth specific objectives of this 
study. 
 
CHAPTER 4 
 
87 
 
4.2 Synergistic/matrix combination assay as a preliminary means of determining MoA 
Fractional inhibition concentration index (FICI) can be used as a preliminary means to 
establish whether the MoA of analogues or metabolites compared to the parent, is retained. 
In this case, this approach was used to determine whether the derived CPZ metabolites 
retained the MoA of the parental compound. Comparison was made between FICI values 
determined for CPZ in combination with a panel of known antituberculosis (anti-TB) drugs 
and the FICI values obtained for the corresponding metabolites in similar combinations 
(Chapter 3). A close correlation between CPZ and each of the active metabolites was 
observed, suggesting that the derivative compounds remained “on target.” Moreover, 
combinations of CPZ with the metabolites yielded FICI values close to 1, indicating an 
additive effect as a result of effective doubling of the concentration (Table 3.2, Chapter 3).6 
 
4.3 Bactericidal and bacteriostatic effect  
Microplate alamar blue assay (MABA) screening was carried out for CPZ, its metabolites or 
anti-TB drugs, singly, with low inoculum of Mtb (H37RvMa). Likewise, a few interesting drug 
combinations discussed previously (Chapter 3) were also prepared using the checkerboard 
assay. The wells with the lowest concentration that exhibited a blue color were plated on 
7H10 solid media for determination of bactericidal/bacteriostatic effects. Colony forming units 
per milliliter (CFU/ml), which is a rough estimate of the number of viable mycobacteria cells 
present in a culture, and the bactericidal/bacteriostatic effect were determined for CPZ, its 
metabolites and the combination pairs (section 7.3.3, Chapter 7); the results are summarized 
in Table 4.1 and Table 4.2;  Graph 4.1 and Graph 4.2. The initial culture, added to 96 well 
plates with the various drugs prepared either singly or in combinations, resulted in ∼104-105 
CFU/ml count. Therefore, individual drugs or combination pairs that exhibited a 99% killing 
effect relative to the number of bacilli in the initial culture (i.e. those which resulted in fewer 
than or equal to 102-103 CFU/ml post exposure) were defined as bactericidal, whereas those 
with greater than ∼102-103 but less than or equal to ∼104-105 CFU/ml were considered 
bacteriostatic. 
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Table 4.1: CFU/ml counts after exposure of Mtb to CPZ, its metabolites and anti-TB drugs 
Compound Blue (MIC99 well) Pink (well after MIC99 well) Bactericidal/Bacteriostatic 
CPZ 7.0 x 101 1 x 105 Bactericidal 
7-hydroxyCPZ (M2) 2.7 x 103 1.078 x 107 Bacteriostatic 
CPZ-N-oxide (M3) 7.0 x 103 9.25 x 106 Bacteriostatic 
Nor-CPZ (M5) 2.6 x 104 5.6 x 106 Bacteriostatic 
INH 2.8 x 102 1.0025 x 107 Bactericidal 
Fusidic acid 1.223 x 105 5.0 x 106 Bacteriostatic 
RIF 0 4.68 x 106 Bactericidal 
BDQ 8.5 x 102 5.5 x 105 Bactericidal 
SPEC 4.667 x 101 0 Bactericidal 
 
INH – isoniazid; RIF – rifampicin; BDQ – bedaquiline; SPEC - spectinomycin; initial culture - 5.2 x 104
 
CFU/ml; 
controls with no drug - 8.3 x 107 CFU/ml; the data are representative of at least two independent biological 
replicates 
 
 
 
Graph 4.1 Bactericidal or bacteriostatic effect (CPZ & its metabolites); INH (bactericidal) and fusidic acid 
(bacteriostatic) are positive controls; initial culture and culture with no treatment are the negative controls; the 
data are representative of at least two independent biological replicates 
 
 
A bactericidal effect was observed for CPZ. However, 7-hydroxyCPZ (M2), nor-CPZ (M5) 
and CPZ-N-oxide (M3) exhibited a bacteriostatic effect indicating that the killing effect of 
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CPZ is bactericidal due to the bioactivity contribution of the three metabolites, M2, M5 and 
M3. Nevertheless, it was previously reported that CPZ and 7-hydroxyCPZ (M2) are 
bacteriostatic against gram-positive and gram-negative bacteria.7,8  
 
Table 4.2: CFU/ml counts of combinations of CPZ or its metabolites with anti-TB drugs 
Combinations Blue well (MIC99) Pink well (MIC99) Bactericidal/Bacteriostatic effect 
RIF 
CPZ 
2.0 x 104  4 x 106  Bacteriostatic 
RIF 
7-hydroxyCPZ (M2) 6.1 x 10
4  8.2 x 107 Bacteriostatic 
RIF  
Nor-CPZ (M5) 9.0  x 10
2   1.03 x 107 Bactericidal 
RIF 
CPZ-N-oxide (M3) 9 x 10
2 2.2 x 107 Bactericidal 
BDQ 
CPZ 1.643 x 10
4 4.9 x 106 Bacteriostatic 
BDQ 
7-hydroxyCPZ (M2) 1.575 x 10
3 1.1 x 106 Bactericidal 
BDQ 
Nor-CPZ (M5) 6.417 x 10
1 6.4 x 106 Bacteriostatic 
BDQ 
CPZ-N-oxide (M3) 6.29 x 10
4 3.6 x 106 Bacteriostatic 
SPEC 
CPZ 9.425 x 10
3 5.0 x 105 Bacteriostatic 
SPEC 
7-hydroxyCPZ (M2) 2.7 x 10
3 1.2 x 106 Bacteriostatic 
SPEC 
Nor-CPZ (M5) 4.619 x 10
4 6.5 x 105 Bacteriostatic 
SPEC 
CPZ-N-oxide (M3) 0 3.4 x 10
6 Bactericidal 
 
Initial culture - 5.2 x 1104
 
CFU/ml; controls with no drug - 8.3 x 107 CFU/ml; the data are representative of at least 
two independent biological replicates 
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Graph 4.2 Bactericidal & bacteriostatic effect (combinations); INH (bactericidal) and fusidic acid (bacteriostatic) 
are positive controls; initial culture and culture with no treatment are the negative controls; the data are 
representative of at least two independent biological replicates 
 
 
 
The determination of the bactericidal and bacteriostatic effect of some of the combinations 
that demonstrated synergistic interactions might provide some insight into the effect 
experienced by mycobacteria when exposed to the different pairs of drugs. RIF (bactericidal) 
in combination with CPZ-N-oxide (M3) (bacteriostatic) and nor-CPZ (M5) (bacteriostatic) 
exhibited a bactericidal effect while in combination with CPZ (bactericidal) and 7-
hydroxyCPZ (M2) (bacteriostatic), a bacteriostatic effect was observed. SPEC (bactericidal) 
with M3 was bactericidal but bacteriostatic with CPZ, M2 and M5. BDQ (bactericidal) was 
bacteriostatic with CPZ, M3 and M5 but bactericidal with M2.  
 
No particular pattern can be drawn from the different effects of the combinations used in this 
experiment. It can only be concluded from these findings that despite RIF, BDQ and SPEC 
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being bactericidal9–11 when combined with CPZ and its metabolites, the dominating effect at 
the lowest synergistic concentrations of the partners becomes bacteriostatic. This difference 
can be attributed to the reduced concentrations of the partner drugs in the wells in which  
synergism is observed: that is, inhibition of growth occurs at lower concentrations and can 
be mediated at a concentration of drug(s) that is bacteriostatic, in contrast to the higher 
inhibition concentrations recorded for compounds tested individually.  
 
Similar observations were made previously by Bonapace et al.,12 who explained that the 
inconsistencies exhibited in the two techniques (liquid versus solid media assays) may be 
due to the fact that they measure two different endpoints: bacterial growth inhibition and 
bacterial killing, respectively. Minimum bactericidal synergistic concentrations should 
therefore be determined for the best combinations discussed here in order to inform the 
development of bactericidal drug combinations.13 
 
4.4 Spontaneous resistant mutant generation 
An attempt to generate spontaneous resistant mutant strains of Mtb on 7H10 solid media 
containing 5 x, 10 x, 15 x and 20 x MIC99 concentrations of CPZ, 7-hydroxyCPZ (M2) and 
nor-CPZ (M5) was carried out in this study (section 7.3.4, Chapter 7) but was not successful, 
suggesting that the MoA of the parent and the metabolites is likely pleiotropic and, 
potentially, similar. This is not surprising because, as of now, there are no reports of 
generation of spontaneous mutants of Mtb that are resistant to CPZ. The MoA of 
phenothiazines was elusive for some time. It was originally proposed that the compounds 
function as efflux pump inhibitors.14–16 However, as mentioned earlier, in vitro assays 
strongly suggested that phenothiazines target the type II NADH:menaquinone 
oxidoreductase which is essential for respiration in mycobacteria. Subsequently, it is thought 
that inhibition of the dehydrogenase would presumably result in inhibition of the cytochrome 
bd and cytochrome aa3 complexes and thereby would prevent the organism from entering a 
state of non-replicating persistence.1,3,17 In addition, it is possible that blocking the electron 
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flow to the menaquinone may result in downstream inhibition effects on energy-dependent 
functions such as efflux, which would lead to increased accumulation of a drug in 
combination with a phenothiazine such as CPZ,18 as reported in the synergistic/matrix 
combination assay discussed in Chapter 3. Based on these observations, it can be 
presumed that inhibition of the dehydrogenase causes alterations of various functions of the 
respiration system of the bacilli, causing the phenothiazines to behave as though they 
interact with different targets. It is therefore unlikely that the Mtb respiration complex would 
tolerate mutations, hence making it difficult to raise spontaneous mutants.    
 
4.5 Transcriptional response of cydA gene 
Electron transport in mycobacteria is initiated by the activity of various NADH and succinate 
dehydrogenases (SDH), which transfer electrons to menaquinone. Electrons are then 
passed to various cytochrome oxidases, whose activity is determined by the prevailing 
oxygen availability.1,3,4 Recent work from Berney et al.4 suggests that cytochrome bd 
oxidase, a non-proton-pumping terminal oxidase, is a relevant target for drugs: these authors 
suggest that cytochrome bd oxidase inhibitors might be usefully combined with BDQ, an 
inhibitor of adenosine triphosphate (ATP) synthase and characterized by a slow killing effect. 
Specifically, they propose that inhibition of ATP synthase may not be sufficient due to the 
subsequent induction of cytochrome bd oxidase expression, which relieves the back 
pressure on the electron transport chain and allows the mycobacterium to prolong 
maintenance of its membrane potential in the absence of ATP synthase activity leading to 
extrusion of a drug from the bacilli. This claim is supported by the results obtained here, in 
Chapter 3, Table 3.5 where a 508-fold reduction of the MIC99 of BDQ in combination with 
CPZ was observed.  
 
Arora et al.5 demonstrated that there is a risk in designing drugs that only inhibit the 
respiratory bc1 complex, due to the fact that it has affinity for many compounds such as the 
imidazo[1,2 α]pyridines, hence exhibiting “promiscuity.” Moreover, inhibition of bc1 leads to 
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up-regulation of the cytochrome bd oxidase and cydDC genes, which are part of an 
alternative respiratory complex. Since CPZ has previously been reported to inhibit the 
dehydrogenase activity,3,19–22 and has been shown to induce expression of cydAB genes that 
encode the cytochrome bd oxidase,17 cydA (Rv1623c) gene was hence selected for this 
study (section 7.3.5, Chapter 7).  
 
SPEC, a protein synthesis inhibitor in bacteria23 was used as a negative control. H3DTB-
0000941, an imidazopyridine compound currently in development at the University of Cape 
Town (UCT), Drug Discovery and Development (H3-D) Center, was found to up-regulate 
cydA, and was hence used as a positive control. An untreated sample was also included as 
a negative control. Graph 4.3 illustrates the effect on cydA expression following exposure of 
Mtb to CPZ, its metabolites and some of their combinations.  
 
 
Graph 4.3 cydA expression in Mtb treated with CPZ, its metabolites and some combinations; 6h treated samples 
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As expected, the untreated and SPEC treated samples exhibited very low cydA expression 
levels whereas the positive control treated sample exhibited a 3.8-fold up-regulation of cydA 
gene. The highest expression of cydA gene (4.6-fold up-regulation) was observed in Mtb 
treated with the parent drug CPZ, consistent with previous analyses of the CPZ-induced 
mycobacterial transcriptome.17 A 2-fold up-regulation of cydA was observed for Mtb treated 
with M1, M2 and M3.  With M4b, M5 and M6b about 1.5-fold up-regulation of the gene was 
observed but was not significant since it was comparable to the SPEC treated sample. It is, 
however, important to note that the initial concentrations that were utilized in the combination 
assays (Chapter 3) for M1, M4b and M6b (1991, 1900 and 2078µM) were much higher than 
the concentrations used in the transcriptional response experiment (140µM). At high 
concentrations, the three inactive metabolites significantly reduced the MIC99 of some of the 
anti-TB drugs used in the combination assays. This suggests that higher cydA gene 
expression may possibly be observed at much higher concentrations of the three 
metabolites.    
 
To further investigate observations made in the combination assays discussed in Chapter 3, 
two of the most promising combinations were selected for the transcriptional response 
experiment. Interestingly, combinations of RIF and two metabolites M2 and M5 exhibited at 
least a 2-fold up-regulation of cydA while a down regulation was observed for the RIF treated 
sample. It is also worth noting here that to test for cydA gene expression, MIC99 
concentrations of the partners used, were 2.5 times lower than the concentrations used for 
M2 and M5 when tested singly. It is possible that higher cydA gene expression may perhaps 
have been observed had the combinations been prepared with 140µM of the metabolites. 
 
Murima et al.24 recently described the use of a medium-throughput micro-fluidic (fluidigm) 
assay to explore the MoA of synthesized analogues in relation to the parent compounds 
using a “diagnostic” transcriptional response in Mtb. Analogous to that study, the findings 
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here strongly suggest that the metabolites do retain the same MoA as the parental 
compound, CPZ.   
 
4.6 Determination of MIC99 of CPZ and its metabolites against cytochrome bd oxidase 
Mtb mutant strains  
Having observed an up-regulation of cydA (section 4.3), there was need to ascertain 
whether CPZ or its metabolites retained their activity against an Mtb strain lacking a 
functional cytochrome bd oxidase. To this end, CPZ, 7-hydroxyCPZ (M2), nor-CPZ (M5) and 
CPZ-N-oxide (M3) were tested against the ΔcydBDC mutant5 as well as ΔcydA and ΔcydAB 
mutants (Moosa, Mizrahi, Warner unpublished) of Mtb in which cytochrome bd oxidase 
function is eliminated (Table 7.1, section 7.3.1, Chapter 7). The results in Table 4.3 indicate 
that all the four compounds retained their activity relative to H37RvMa (wild-type) confirming 
further that CPZ metabolites remain “on target.” It can also be deduced here that, despite the 
fact that these compounds cause an up-regulation of the genes in the cydABCD operon, 
deletion effect of the cytochrome bd oxidase-encoding genes does not compromise the 
killing effect observed when the compounds inhibit type II NADH. This result is consistent 
with the suggestion made by Weinstein et al.3 who postulated that inhibition of the 
dehydrogenase by trifluoperazine, a phenothiazine, may result in an inhibition effect on both 
respiratory branches, cytochrome bd and a cytochrome aa3 systems, ultimately leading to 
the death of the mycobacteria. 
 
Table 4.3: MIC99 of CPZ or its metabolites against the cytochrome bd oxidase Mtb knockout 
mutant strains (in GAST/Fe minimum media) 
Compound 
MIC99 (µM) 
H37RvMa  ∆cydKO ∆cydA  ∆cydAB  
CPZ 28.1 28.1 28.1 28.1 
7-hydroxyCPZ (M2) 59.7 59.7 119.5+34.53 59.7 
Nor-CPZ (M5) 65.6 65.6 65.6 65.6 
CPZ-N-oxide (M4b) 497.2 497.2 497.2 497.2 
CDM143* 0.156+0.18  0.0001  0.0097+0.01 0.0012 
 
. *Positive control – imidazopyridine in development at H3-D Center; targets QcrB 
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4.7 Summary discussion 
Based on prior identification of type II NADH:menaquinone oxidoreductase as the target for 
CPZ,1,3,17 several approaches were used in this study to interrogate the MoA of CPZ 
metabolites. With the use of different approaches discussed, it was established here that 
metabolites of CPZ retain the same MoA as the parent. The results also suggest that 
inhibition of NADH dehydrogenase is effective in arresting both respiratory complexes.1,3  
This is contrary to the ATP synthase and the bc1 complex inhibition effects reported for BDQ 
and imidazo[1,2 α]pyridines respectively, that result in an up-regulation of the cyd genes 
encoding the alternative cytochrome bd complex leading to a delayed killing effect of the 
mycobacteria.4,5 In addition, it has been demonstrated here that the use of multiple assays 
for investigation of the MoA of drug(s), is more beneficial than the use of a single assay. 
However, with the failure to raise spontaneous Mtb mutants, it still remains unclear whether 
CPZ and its metabolites are able to interact with one or more targets.   
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CHAPTER 5 
MUTATIONS IN 16S rRNA CONFERRING SPECTINOMYCIN RESISTANCE IN 
MYCOBACTERIUM TUBERCULOSIS (Mtb) 
 
5.1 Introduction 
With a renewed interest in the possibility of exploiting alternative strategies to address the 
well-documented bottlenecks in antibiotic development,1 the potential to repurpose approved 
drugs for use as novel anti-infective agents,2–5 or to use them as leads in drug repositioning 
strategies, is an attractive approach. Ramon-Garcia et al.6 demonstrated that spectinomycin 
(SPEC) exhibits very low antimycobacterial activity on its own but can be combined with 
other drugs to produce a synergistic effect. Based on their observations, as well as the 
results presented in Chapter 3, SPEC was selected for further investigations of the 
mechanism of action (MoA). SPEC (Figure 5.1) is an aminoglycoside produced by the 
bacterium Streptomyces spectabilis and used to treat gonorrhea.7,8 
 
 
Figure 5.1 SPEC, chlorpromazine (CPZ) and its metabolites 
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In the results discussed in Chapter 3, SPEC was shown to have synergistic interactions with 
CPZ or its metabolites (Figure 5.1) against Mycobacterium smegmatis (Msm) and M. 
tuberculosis (Mtb). In fact, in combination with CPZ, a 128-fold reduction of its MIC99 value 
was observed against Mtb (Table 5.2). Moreover, Lee et al.9 carried out a structure activity 
relationship (SAR) study of SPEC leading to the discovery of derivatives known as 
spectinamides. The analogues exhibited a 50-fold higher antimycobacterial activity 
compared to the parent, against sensitive and resistant strains of Mtb and with an ability to 
overcome efflux.  Based on findings from these studies, SPEC is highly attractive for further 
development as an anti-TB drug however, it raised questions on whether it is suitable for 
further development due to its ability to synergize with many classes of compounds, an 
indication of off-target activity.   
 
It therefore became necessary to explore the MoA of SPEC which, in combination with CPZ 
and its metabolites, resulted in the highest synergistic effect (Chapter 3). In addition, we 
wanted to establish why it synergizes with a wide range of drugs. The MoA of SPEC has 
been extensively investigated in bacteria. 16S ribosomal mutations in Escherichia coli and 
Neisseria gonorrhoeae have been reported before.7,10–15 For instance, in E. coli, SPEC has 
been reported to be an inhibitor of protein translation by binding to the bacterial 30S 
ribosomal subunit. It specifically interacts directly with 16S rRNA and inhibits the elongation 
factor G (EF-G)-catalyzed translocation of the peptidyl-tRNA from the A site to the P site 
during polypeptide elongation.13,16 Reports also indicate that the interaction of SPEC with 
16S rRNA is in the upper stem of helix 34, close to the base-paired C1063G1064U1065 and 
A1191C1192G1193 where resistance to the drug has been mapped in E. coli.7,10,17 In N. 
gonorrhoeae, only a single nucleotide polymorphism (SNP), specifically a C1192U transition, 
in 16S rRNA has been verified to result in high-level SPEC resistance.11,12 Nonetheless, the 
MoA of SPEC in Mtb remains unknown.  
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5.2 SPEC in combination with CPZ or its metabolites against Msm (mc2155) and Mtb 
(H37RvMa) 
A compilation of the combination assay results of SPEC with CPZ or its metabolites 
(discussed in Chapter 3) was carried out to bring into perspective why SPEC was selected 
for spontaneous mutant generation in Mtb. A summary of the MIC99 and the lowest MIC99 
achieved in the various combinations of CPZ or its metabolites with SPEC, and the fractional 
inhibitory concentration indices (FICI values) against Msm (mc2155) and Mtb (H37RvMa), 
are given in Table 5.1 -Table 5.4.  
 
As defined in Chapter 3, it should be noted that synergy is assigned where fractional 
inhibition concentration index (FICI) < 0.5; an FICI >4 is antagonistic while any value falling 
in between is additive/no effect.6,18–20 Evidently, synergism was observed in most of the 
combinations of SPEC with CPZ or its active metabolites (FICI < 0.5). The highest FICIs 
observed were with 7-hydroxyCPZ (M2) at 0.19 and 0.13 against Msm and Mtb, respectively 
(Table 5.1 & Table 5.4). Interestingly, a high reduction of the MIC99 values of SPEC was 
observed for most of the combinations, the highest being with CPZ (128-fold, Table 5.2) 
against Mtb. 
 
Table 5.1: FICI of CPZ or its metabolites in combination with SPEC, against Msm 
Drugs/Compound  MIC99 (µM), 
singly 
MIC99 (µM) in combination MIC99 fold 
reduction 
FIC FICI 
SPEC 
CPZ 
84.12+24.05 5.25 16 0.062 0.31 
117.27 29.32  0.250 
SPEC 
7-hydroxyCPZ (M2) 
84.12+24.05 5.25+10.53 16 0.062 0.19 
124.44+15.91 15.56+2.47  0.125 
SPEC  
CPZ-N-oxide (M3) 
168.22+24.05 84.12 2 0.500 0.63 
995.43 124.44+71.84  0.125 
SPEC 
nor-CPZ (M5) 
84.12 5.25+4 16 0.062 0.31 
136.70+31.82 34.18+4.51  0.250 
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Table 5.2: FICI of CPZ or its metabolites in combination with SPEC, against Mtb 
Drugs/Compound MIC99 (µM), 
singly 
MIC99 (µM) in combination MIC99 fold 
reduction 
FIC FICI 
SPEC 
CPZ 
168.22+97.14 1.31+1 128.4 0.0078 0.26 
29.32+6.01 7.32+4.51  0.250 
SPEC 
7-hydroxyCPZ (M2) 
336.47 21.04 16 0.063 0.13 
124.44+14.74 7.76  0.063 
SPEC 
CPZ-N-oxide (M3) 
336.47 
NC 
497.73 
SPEC 
nor-CPZ (M5) 
336.47 21.04 16 0.063 0.19 
68.34 8.53  0.125 
 
NC – No Change 
 
In combination with the inactive CPZ metabolites (Table 5.3 and Table 5.4), at least a 2-fold 
reduction in MIC99 of SPEC was observed but, most importantly, the highest recorded at 16-
fold against Msm. This demonstrates that, despite the absence of a killing effect of M1, M4b 
& M6b, an additional MoA of the pairs was at play. Hence, generation of spontaneous 
mutant strains of SPEC followed. 
 
Table 5.3: Inactive metabolites of CPZ in combination with SPEC against Msm 
Drugs/Compound  MIC99 (µM), singly MIC99 (µM) in 
combination 
MIC99  fold reduction 
SPEC 
CPZ sulfoxide (M1) 
168.22+48 10.52+3.1 16-fold 
>1990.89 1990.89 
SPEC 
CPZ-N-S-dioxide (M4b) 
84.12 42.05 2-fold 
>1900.10 1900.10 
SPEC  
nor-CPZ sulfoxide (M6b) 
84.12 21.04+5.43 4-fold 
>2077.89 64.92+14.74 
 
Table 5.4: Inactive metabolites of CPZ in combination with SPEC against Mtb 
Drugs/Compound MIC99 (µM), singly MIC99 (µM) in combination MIC99  fold reduction 
SPEC 
CPZ sulfoxide (M1) 
168.22+48.56 42.05+12.14 4-fold 
>1990.89 497.73 
SPEC 
CPZ-N-S-dioxide (M4b) 
336.47 168.22 2-fold 
>1900.10 950.04  
SPEC  
nor-CPZ sulfoxide (M6b) 
336.47 84.12+12.14 4-fold 
>2077.89 519.48 
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5.3 Frequency and identification of SPEC-resistant (SPECR) mutations  
The frequency of the SPECR mutants of Mtb was determined by plating 108 -109 cells of 
logarithmic phase H37RvMa strain on standard media broth, 7H10 plates containing 1.3 mM 
of SPEC, a concentration 5-fold higher than the MIC99. The colonies typically appeared and 
were scored after 4 weeks’ incubation at 37°C. The spontaneous mutants arose at a 
frequency of 2.09 x 10-6, comparable to the value reported for spectinamides mutant strains.9 
Five individual colonies were picked, grown in standard 7H9 ADC media, and tested for 
SPEC susceptibility (section 7.3.6, Chapter 7). All SPECR mutants showed a >64-fold 
increase in MIC99 (section 5.4, Table 5.8). 
 
As discussed above, SPECR mutations have been primarily mapped to the 16S rRNA in 
other bacteria.11,13–15 According to Lee et al.,9 exposure of Mtb to spectinamides led to 
mutations in the rpsE gene, encoding ribosomal protein S5. Consequently, 16S rRNA rrs 
(MTB000019) and rpsE genes were sequenced in the five SPECR mutants to determine if 
similar mutations were responsible for resistance in Mtb (section 7.3.6.4, Chapter 7). Point 
mutations as a result of a guanine-to-thymine (G-T) transition at position 1379 in the rrs gene 
generated MtbSR1 strain. Mutant MtbSR3 strain was a result of a replacement of adenine by 
a guanine in position 1183 in the same gene. The other three mutants, interestingly, had an 
insertion of cytosine at position 926 (Table 5.5).  
 
Table 5.5: Sequencing results of SPECR mutant and H37RvMa strains 
Strain Mutation in rrs gene 
Mtb H37RvMa No mutation 
MtbSR1  G1379T 
MtbSR2  Insertion of C (926) 
MtbSR3  A1183G 
MtbSR4 Insertion of C (926) 
MtbSR5 Insertion of C (926) 
 
G – guanine; T – thymine; A – adenine; C - cytosine 
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To our knowledge, this is the first time that the insertion of cytosine at position 926 has been 
described as a mechanism for SPEC resistance in bacteria. It is worth noting that targeted 
sequencing revealed that none of the five SPECR isolates carried additional rpsE 
polymorphisms. However, in E. coli, mutations in the gene, are reported to cause resistance 
to SPEC.22  
 
A closer look at the predicted structures of rrs RNA sequences of the SPEC mutants in 
Figure 5.2 in relation to H37RvMa (wild-type), indicate that a single nucleotide substitution or 
insertion can cause a dramatic change in folding pattern of rrs secondary structure. This is 
mainly observed for instance in MtbSR1 mutant strain with fewer structural modifications 
predicted for MtbSR3 and MtbSR4.  
 
 
Figure 5.2 Structures of the rrs genes of SPECR mutant Mtb strains (drawn using CentroidFold software21) 
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SPEC dependence has been reported in Bacillus subtilis when double mutations occur in the 
ribosomal genes.23 This lack of dependence was confirmed by the ability of all SPECR Mtb 
mutants to grow in the absence of SPEC.  
 
5.3.1 Fitness cost of SPECR mutant strains 
Most bacteria possess more than one copy of 16S rRNA gene however, Mtb carries only 
one copy.24,25 This prompted the need to look for any fitness cost associated with the 
mutation in 16S rRNA (section 7.3.6.5, Chapter 7). The rrs gene structural changes 
considerably affected the growth kinetics of the mutant strains (Graph 5.1, Table 5.6) and 
the morphology of the resistant mutant colonies (Appendix 10A).  
 
 
Graph 5.1 Growth curve for SPECR Mtb mutant strains; OD600 – optical density at 600nm wavelength; the data 
are representative of at least two independent biological replicates 
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Table 5.6: CFU/ml counts of SPECR mutant strains  
Strain 
Days 
0 1 3 4 5 6 
H37RvMa 3.5 x 105 7.5 x 105 6.8 x 106 4.72 x 107 4.2 x 108 7.0 x 108 
MtbSR1 4.2 x 105  7.5 x 105 7.5 x 106 4.15 x 107 1.95 x 108 6.65 x 109 
MtbSR2 2.25 x 105 4.55 x 105 7.0 x 105 2.4467 x 107 3.0 x 107 1.0 x 108 
MtbSR3 3.5 x 105 9.0 x 105 6.9 x 106 7.16 x 107 7.4 x 108 9.0 x 108 
MtbSR4 4.53 x 105 7.0 x 105 5.5 x 106 4.45 x 107 6.0 x 107 2.5 x 109 
MtbSR5 2.15 x 105 3.3 x 105 1.0 x 105 7 x 105 2.0 x 107 1.0 x 108 
 
The data are representative of at least two independent biological replicates 
 
 
Surprisingly, the mutations that occurred in rrs genes of MtbSR1, MtbSR3 and MtbSR4 
strains resulted in a reproducibly faster growth rate compared to the wild-type (H37RvMa) 
strain as assessed by optical density (OD600,  Graph 5.1). On the other hand, slower growth 
was observed for MtbSR2 and MtbSR5 strains (Graph 5.1). MtbSR2, MtbSR4 and MtbSR5 
colonies appeared to be smaller and fewer compared to the ones of H37RvMa, MtbSR1, and 
MtbSR3 (Appendix 10A). Interestingly, lower doubling times of MtbSR1, MtbSR3, MtbSR4 
and MtbSR5 (20.18, 19.24, 19.79 and 20.47h respectively; Table 5.7) compared to 
H37RvMa wild-type strain (21.65h), were observed. However, MtbSR2 exhibited longer 
doubling time.  
 
Table 5.7: Strain doubling times calculated during growth in liquid media 
Strain Doubling time (h) 
H37RvMa 21.65 
MtbSR1  20.18 
MtbSR2  22.80 
MtbSR3  19.24 
MtbSR4  19.79 
MtbSR5  20.47 
 
Doubling times are calculated using changes in OD600 value over 24 hour intervals; the data are representative of 
at least two independent biological replicates 
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5.4 Susceptibility testing singly and in combination of SPEC with CPZ or its 
metabolites on SPECR mutant strains  
Table 5.8 summarizes the MIC99 determined for SPEC, CPZ, CPZ metabolites and anti-TB 
drugs against the resistant mutants (section 7.3.1, Chapter 7). The results here indicate that 
a >64-fold increase of the MIC99 of SPEC against the mutant strains relative to wild-type 
strain, occurred. On the other hand, the MIC99 of CPZ, CPZ metabolites and the anti-TB 
drugs remained unaffected against the mutant strains relative to the wild-type strain, 
confirming absence of cross-resistance. However, it was noted that less resistance to SPEC 
was exhibited by MtbSR4 and MtbSR5 mutant strains (MIC99 16823 µM) compared to the 
other mutants (MtbSR1, MtbSR2 and MtbSR3) which resulted in SPEC MIC99 >16823 µM. 
 
Table 5.8: MIC99 of various drugs against different SPECR mutant strains 
Drugs 
MIC99 against different resistant colonies (µM) 
MtbSR1 MtbSR2 MtbSR3 MtbSR4 MtbSR5 H37RvMa 
CPZ 59 29+17.3 59 29 29 59 
7-HydroxyCPZ (M2) 62 62 62 31 31 62 
Nor-CPZ (M5) 68 68 68 34 34 68 
CPZ-N-S-dioxide (M4b) >1900 >1900 >1900 >1900 >1900 >1900 
SPEC >16823 >16823 >16823 16823 16823 263 
STRP 0.22 0.22 0.11+0.06 0.22 0.22 0.45+0.16 
KANA 4.46 4.46 2.23 4.46 4.46 4.46 
GENT 6.98 6.98 6.98 6.98 6.98 6.98 
HYGR 15.8 15.8 15.8 15.8 15.8 15.8 
CLMP 25.79 25.79 25.79 12.9 12.9 25.79 
RIF 0.004 0.004 0.008+0.02 0.008+0.02 0.002 0.008+0.02 
25-O-DesacetylRIF 0.013 0.0067 0.013 0.0067 0.013 0.013 
INH 0.2 0.2 0.2 0.2 0.2 0.2 
EMB 6.01+1.73 3 3+01.73 3 3 6.01 
BDQ 0.47 0.94+0.27 0.47 0.47 0.47 0.47 
LEVO 2.31+0.7 1.15 1.15 1.15 1.15 2.31 
 
STRP – streptomycin, KANA – kanamycin, RIF – rifampicin, INH – isoniazid, BDQ – bedaquiline; GENT – 
gentamycin; HYGR – hygromycin; CLMP – chloramphenical; 25-O-desacetylRIF - 25-O-desacetylrifampicin; EMB 
– ethambutol; LEVO – levofloxacin; H37RvMa – wild-type 
 
As shown in Table 5.9, combining SPEC with CPZ or its metabolites did not restore the 
antimycobacterial activity of the antibiotic against MtbSR1 and MtbSR5 mutant strains. 
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Antimycobacterial activity was only observed for CPZ or its metabolites, further confirming 
the absence of cross-resistance. This also suggests that the synergism observed in similar 
combinations against the wild-type strain is as a result of drug pairs acting on different 
targets, and is not a function of a non-specific property. That is, SPEC synergizes with other 
drugs owing to its ability to disrupt 16S rRNA function. 
  
Table 5.9: Combinations of SPEC with CPZ or its metabolites against MtbSR1 and MtbSR5 
mutant colonies 
Drugs/Compound  MIC99 (µM), singly MIC99 (µM) in combination 
SPECR   (MtbSR1) 
SPEC 
CPZ 
>673 NC 
59 NC 
SPEC 
7-HydroxyCPZ (M2) 
>673 NC 
62 NC 
SPEC 
Nor-CPZ (M5) 
>673 NC 
68 NC 
SPEC 
CPZ-N-S-dioxide (M4b) 
>673 NC 
>1900 NC 
SPECR (MtbSR5) 
SPEC 
CPZ 
>673 NC 
29 NC 
SPEC 
7-HydroxyCPZ (M2) 
>673 NC 
31 NC 
SPEC 
Nor-CPZ (M5) 
>673 NC 
34 NC 
SPEC 
CPZ-N-S-dioxide (M4b) 
>673 NC 
>1900 NC 
 
NC – No Change 
 
5.5 Summary discussion 
The 16S rRNA rrs gene (MTB000019) was identified in this study as the target for SPEC in 
Mtb. The target has also been previously reported in other bacteria that possess more than 
one copy of rrs. However, Mtb carries only one copy suggesting that the gene may 
potentially be essential for survival.24,25 Mutations due to an insertion of a cytosine in the 
gene have not previously been reported, making this a unique finding in this study. 
CHAPTER 5 
 
109 
 
Generally, the SNPs resulted in a dramatic change in mycobacterial growth kinetics. The 
growth rate of the SPECR mutant strains was found to either be higher in MtbSR1, MtbSR3 
and MtbSR4 mutants or lower in MtbSR2, and MtbSR5 strains relative to H37RvMa strain. 
This indicated that point mutations due to a replacement of a nucleotide resulted in a positive 
growth impact on the mycobacteria, while an insertion of an extra base led to a growth-
defect except for MtbSR4 that grew fast but with smaller colonies relative to wild-type. In 
addition, it has been demonstrated here that the spontaneous mutations generated in Mtb 
were selective for SPEC given that cross-resistance was not observed. 
 
It can also be inferred that synergistic interactions exhibited in combinations of SPEC with 
other drugs against Msm and Mtb may actually be beneficial. This is because it has been 
shown here that SPEC does not interact with several targets but specifically binds to the rrs 
gene that encodes the 16S rRNA. Hence, it can be deduced that an off-target activity is 
unlikely to occur with SPEC, qualifying it as a suitable partner for combination therapy for TB 
treatment.  
 
A limitation of SPEC is that it is subject to efflux; this motivated the work by Lee et al.9 who 
showed that engineering the drug to the spectinamide analogues provided a powerful way to 
circumvent this problem. It would be great if future research could look at combinations of 
spectinamides with CPZ. If there’s no effect, then one can infer that CPZ is potentiating 
SPEC by inhibiting Rv1258c function that encodes an efflux pump in Mtb, and is thought to 
cause drug tolerance. 
  
CHAPTER 5 
 
110 
 
REFERENCES 
(1)  Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for Bad Bugs: 
Confronting the Challenges of Antibacterial Discovery. Nat. Rev. Drug Discov. 2007, 
6, 29–40. 
(2)  Fischbach, M. A.; Walsh, C. T. Antibiotics for Emerging Pathogens. Science 2009, 
325, 1089–93. 
(3)  Walsh, C. T.; Fischbach, M. A. Repurposing Libraries of Eukaryotic Protein Kinase 
Inhibitors for Antibiotic Discovery. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 1689–90. 
(4)  Palomino, J. C.; Martin, A. Is Repositioning of Drugs A Viable Alternative in the 
Treatment of Tuberculosis? J. Antimicrob. Chemother. 2013, 68, 275–83. 
(5)  Nzila, A.; Ma, Z.; Chibale, K. Drug Repositioning in the Treatment of Malaria and TB. 
Future Med. Chem. 2011, 3, 1413–26. 
(6)  Ramón-García, S.; Ng, C.; Anderson, H.; Chao, J. D.; Zheng, X.; Pfeifer, T.; Av-Gay, 
Y.; Roberge, M.; Thompson, C. J. Synergistic Drug Combinations for Tuberculosis 
Therapy Identified by A Novel High-Throughput Screen. Antimicrob. Agents 
Chemother. 2011, 55, 3861–9. 
(7)  Unemo, M.; Golparian, D.; Skogen, V.; Olsen, A. O.; Moi, H.; Syversen, G.; 
Hjelmevoll, S. O. Neisseria gonorrhoeae Strain with High-Level Resistance to 
Spectinomycin due to A Novel Resistance Mechanism (mutated Ribosomal Protein 
S5) Verified in Norway. Antimicrob. Agents Chemother. 2013, 57, 1057–61. 
(8)  Duncan, W. C.; Holder, W. R.; Roberts, D. P.; Knox, J. M. Treatment of Gonorrhea 
with Spectinomycin Hydrochloride: Comparison with Standard Penicillin Schedules. 
Antimicrob. Agents Chemother. 1972, 1, 210–4. 
(9)  Lee, R. E.; Hurdle, J. G.; Liu, J.; Bruhn, D. F.; Matt, T.; Scherman, M. S.; Vaddady, P. 
K.; Zheng, Z.; Qi, J.; Akbergenov, R.; Das, S.; Madhura, D. B.; Rathi, C.; Trivedi, A.; 
Villellas, C.; Lee, R. B.; Rakesh; Waidyarachchi, S. L.; Sun, D.; McNeil, M. R.; Ainsa, 
J. A.; Boshoff, H. I.; Gonzalez-Juarrero, M.; Meibohm, B.; Böttger, E. C.; Lenaerts, A. 
J. Spectinamides: A New Class of Semisynthetic Antituberculosis Agents that 
Overcome Native Drug Efflux. Nat. Med. 2014, 20, 152–8. 
(10)  Sigmund, C. D.; Ettayebi, M.; Morgan, E. A. Antibiotic Resistance Mutations in 16S 
and 23S Ribosomal RNA Genes of Escherichia coli. Nucleic Acids Res. 1984, 12, 
4653–4664. 
(11)  Galimand, M.; Gerbaud, G.; Courvalin, P. Spectinomycin Resistance in Neisseria 
Spp. due to Mutations in 16S rRNA. Antimicrob. Agents Chemother. 2000, 44, 1365–
6. 
(12)  Unemo, M.; Fasth, O.; Fredlund, H.; Limnios, A.; Tapsall, J. Phenotypic and Genetic 
Characterization of the 2008 WHO Neisseria gonorrhoeae Reference Strain Panel 
Intended for Global Quality Assurance and Quality Control of Gonococcal 
Antimicrobial Resistance Surveillance for Public Health Purposes. J. Antimicrob. 
Chemother. 2009, 63, 1142–51. 
CHAPTER 5 
 
111 
 
(13)  Bilgin, N.; Richter, A. A.; Ehrenberg, M.; Dahlberg, A. E.; Kurland, C. G. Ribosomal 
RNA and Protein Mutants Resistant to Spectinomycin. EMBO J. 1990, 9, 735–9. 
(14)  O’Connor, M.; Dahlberg, A. E. Isolation of Spectinomycin Resistance Mutations in the 
16S rRNA of Salmonella enterica, Serovar typhimurium and Expression in 
Escherichia coli and Salmonella. Curr. Microbiol. 2002, 45, 429–33. 
(15)  Criswell, D.; Tobiason, V. L.; Lodmell, J. S.; Samuels, D. S. Mutations Conferring 
Aminoglycoside and Spectinomycin Resistance in Borrelia burgdorferi. Antimicrob. 
Agents Chemother. 2006, 50, 445–52. 
(16)  Ramakrishnan, V.; White, S. W. The Structure of Ribosomal Protein S5 Reveals Sites 
of Interaction with 16S rRNA. Nature 1992, 358, 768–71. 
(17)  Brink, M. F.; Brink, G.; Verbeet, M. P.; de Boer, H. A. Spectinomycin Interacts 
Specifically with the Residues G1064 and C1192 in 16S rRNA, thereby Potentially 
Freezing this Molecule into An Inactive Conformation. Nucleic Acids Res. 1994, 22, 
325–31. 
(18)  Reddy, V. M.; Einck, L.; Andries, K.; Nacy, C. A. In Vitro Interactions between New 
Antitubercular Drug Candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 
2010, 54, 2840–6. 
(19)  Kigondu, E. M.; Njoroge, M.; Singh, K.; Njuguna, N.; Warner, D. F.; Chibale, K. 
Synthesis and Synergistic Antimycobacterial Screening of Chlorpromazine and Its 
Metabolites. Med. Chem. Comm 2014, 5, 502–6. 
(20)  Kigondu, E. M.; Wasuna, A.; Warner, D. F.; Chibale, K. Pharmacologically Active 
Metabolites, Combination Screening and Target Identification-Driven Drug 
Repositioning in Antituberculosis Drug Discovery. Bioorg. Med. Chem. 2014, 22, 
4453–61. 
(21)  Sato, K.; Hamada, M.; Asai, K.; Mituyama, T. CENTROIDFOLD: A Web Server for 
RNA Secondary Structure Prediction. Nucleic Acids Res. 2009, 37, W277–80. 
(22)  Bollen, A.; Davies, J.; Ozaki, M.; Mizushima, S. Ribosomal Protein Conferring 
Sensitivity to the Antibiotic Spectinomycin in Escherichia coli. Science 1969, 165, 85–
6. 
(23)  Henkin, T. M.; Campbell, K. M.; Chambliss, G. H. Spectinomycin Dependence in 
Bacillus subtilis. J. Bacteriol. 1979, 137, 1452–5. 
(24)  Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V; 
Eiglmeier, K.; Gas, S.; Barry, C. E.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; 
Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, 
N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; 
Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; Rutter, S.; 
Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; 
Whitehead, S.; Barrell, B. G. Deciphering the Biology of Mycobacterium tuberculosis 
from the Complete Genome Sequence. Nature 1998, 393, 537–44. 
(25)  Alangaden, G. J.; Kreiswirth, B. N.; Aouad, A.; Khetarpal, M.; Igno, F. R.; Moghazeh, 
S. L.; Manavathu, E. K.; Lerner, S. A. Mechanism of Resistance to Amikacin and 
CHAPTER 5 
 
112 
 
Kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1998, 42, 
1295–7.  
 
 
 
 113 
 
 
CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
 
With a growing need to design new chemotherapeutics for tuberculosis (TB) treatment, a 
renewed interest in repurposing and repositioning old drugs is emerging especially due to 
the increasing numbers of drug-resistant cases. Phenothiazines represent one of many 
classes of drugs that have been the focus of research with the aim of modifying their 
structures or their use for anti-TB drug discovery. In this project, the approach adopted was 
to generate metabolites of chlorpromazine (CPZ), a phenothiazine, and carryout combination 
screening with known anti-TB drugs.  
 
The generation and scale-up of CPZ metabolites was successfully carried out and resulted 
in six metabolites, CPZ sulfoxide (M1), 7-hydroxyCPZ (M2), CPZ-N-oxide (M3), CPZ-N-S-
dioxide (M4b), nor-CPZ (M5) and nor-CPZ sulfoxide (M6b). Exposure of CPZ to human and 
rat liver microsomes (HLM & RLM) gave rise to the highest number of metabolites compared 
to the other biotransformation systems used in this study. This further guided the synthesis 
of the metabolites, with the aim of increasing the yield for antimycobacterial screening. 
Optimization of cytochrome P4501A2 (CYP1A2) incubations of CPZ, leading to generation of 
three metabolites (M1, M2, M5), was important for isolation of the hydroxyl metabolite (M2) 
that could potentially be utilized in the synthesis of analogues of this class of compounds for 
TB drug discovery. In future studies, it is recommended that the cytotoxicity, 
physicochemical as well as pharmacokinetic properties are determined for the metabolites 
and compared with the ones of the parent (CPZ). It is expected that the metabolites would 
exhibit superior properties compared to CPZ, and would be better candidates for anti-TB 
combination drug development. The results presented here further suggest that structure 
activity relationship (SAR) studies of this class of compounds should be carried out in future 
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in order to optimize antimycobacterial activity of the compounds for discovery of novel TB 
combination therapy. This may also result in scaffolds with less neural activity.  
 
Combinations of CPZ or its metabolites with anti-TB drugs exhibited synergistic interactions 
with some fractional inhibition concentration indices (FICI) observed below 0.5. The highest 
synergism observed was with spectinomycin (SPEC), a drug used for treatment of 
gonorrhea but has recently interested research groups working in the TB field for 
repurposing and repositioning. Based on the findings here, it is recommended that 
optimization studies of CPZ or its metabolites in combination with SPEC are carried out in 
order to identify appropriate concentrations of the drugs, to be applied in vivo for further 
investigations. Consideration should focus on the use of human dosing and pharmacokinetic 
parameters, in future studies. It is also recommended that combination assays are carried 
out for CPZ or its metabolites with spectinamides in order to establish whether the former 
compounds have an inhibitory effect on Rv1258c efflux pump, based on the findings by Lee 
et al. 
 
Previously, the mechanism of action (MoA) of CPZ had been established and the target was 
identified as type II NADH:menaquinone oxidoreductase responsible for initiating the 
branched aerobic respiratory chain. Here, it has been shown that the MoA of CPZ and its 
metabolites, is similar based on the findings from the different techniques that were used in 
this study. It still remains unclear whether there is a possibility that these compounds interact 
with different targets, given that generation of spontaneous Mycobacterium tuberculosis 
(Mtb) mutants was not achieved. However, Weinstein et al. shed some light on the matter by 
demonstrating that the inhibition of the NADH dehydrogenase by trifluoperazine, a 
phenothiazine, may probably lead to a downstream effect on the cytochrome bd and a 
cytochrome aa3 respiratory complexes that the mycobacteria uses interchangeably 
depending on its environmental conditions. Coupled with the fact that the inhibition effect 
may lead to further downstream effects on the efflux, this is likely to further reduce the 
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chances of inducing spontaneous mutations in the mycobacteria. This may also suggest that 
there are less chances of development of resistance to phenothiazines by Mtb in a clinical 
situation. Nevertheless, it would be worthwhile to use less concentrations of CPZ or its 
metabolites to try and raise Mtb spontaneous mutant strains since the targeted genes maybe 
essential for the survival of the mycobateria. With further optimization of CPZ and its 
metabolites through structure modifications and identification of optimal pharmacokinetic 
properties, the compounds could potentially be incorporated into the current TB regimen 
especially for populations at risk of development of drug resistance. 
 
In addition to the strong synergistic interactions of SPEC in combination with CPZ or its 
metabolites, the antibiotic was also reported to have similar effects when combined with 
other drugs. As a follow-up on these observations, this study sought to explore the MoA of 
the antibiotic. Spontaneous mutant strains of SPEC were raised followed by sequencing of 
16S rRNA rrs gene (MTB000019) of some of the selected mutant colonies. Three mutations 
identified, resulted in some structural changes of the gene and subsequently a change in the 
growth kinetics of the mycobacteria. This finding not only revealed the target for SPEC in 
mycobacteria, but it also suggests that the rrs gene may be essential due to the fact that the 
organisms consist of only one copy of the gene. This was evident from the different growth 
patterns observed for the mutant strains relative to wild-type. However, more studies need to 
be carried out to validate this fact, as well as explore more possible binding sites for SPEC. 
It hence became clear that SPEC’s ability to synergize with many classes of drugs is not due 
to its interaction with several targets as it was initially perceived, because this could have 
been a potential source of undesired activities. Using in vitro techniques, it has been 
established that SPEC is a potential drug for repurposing or repositioning for combination 
therapy TB drug discovery. This is also very evident from the work of Lee et al. who 
successfully designed analogues of SPEC with higher antimycobacterial activity compared 
to the parent, and able to overcome resistance due to efflux. Likewise, based on the findings 
of this project, synergistic interactions between SPEC and CPZ or its metabolites may be 
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due to the ability to overcome efflux. It is therefore recommended that further optimization 
studies are carried out on combinations of these drugs for further development of a 
combination regimen for TB treatment.   
 
Some challenges were nonetheless encountered during this study. Large-scale metabolite 
generation was not viable due to production of few biotransformation products and in low 
amounts, however, chemical synthesis was achieved successfully. As mentioned earlier, full 
elucidation of the MoA of CPZ and its metabolites was also not achieved since Mtb 
spontaneous mutant strains were not successfully raised. Nevertheless, the use of various 
methods discussed in Chapter 4 helped to establish that the MoA of CPZ metabolites is 
most likely similar to that of the parent. In conclusion, some studies were not exhaustively 
carried out due to time constraints but the findings presented here form a good basis for 
further work that could lead to development of an anti-TB combination regimen derived from 
CPZ or its metabolites. 
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CHAPTER 7 
EXPERIMENTAL 
 
 
7.1 Chemicals and reagents 
All chemicals and solvents were purchased from Sigma Aldrich (SA) or Merck (SA). 7-
Hydroxychlorpromazine (7-hydroxyCPZ) (M2) was purchased from Sigma Aldrich (SA). 25-
O-Desacetylrifampicin (25-O-DesacetylRIF) was purchased from American Custom 
Chemicals Corporation (San Diego, USA). Human and rat liver microsomes (HLM & RLM) 
were purchased from XenoTech, LLC (Lenexa) through AiBST (Zimbabwe). The 
recombinant cytochrome P450 (CYP450s) were generously donated by Prof. Guengerich 
(Vanderbilt University, USA), the bioengineered CYP21B3 by Prof. Frances Arnold (Caltech, 
USA) and the actinomycetes by Dr. Marilize Le Roes-Hill (Cape Peninisula University of 
Technology, SA). Mycobacterium tuberculosis (Mtb) H37Rv wild-type (H37RvMa) was 
donated by Dr. C. Sassetti’s laboratory, University of Massachusetts while the cytochrome 
bd oxidase knockout mutant strains ∆cydKO, ∆cydA and ∆cydAB were prepared from 
H37RvMa strain, in our Molecular Mycobacteriology Research Unit (MMRU) laboratory. The 
details of the knockout mutant strains are provided in Table 7.1. 
 
Table 7.1: Cytochrome bd oxidase mutant strains  
Strain Details Reference 
∆cydKO Deletion of the 3’ end of cydB, deletion of the entire cydD and deletion of 
the 5’ end of cydC. 
Arora et al.1 
∆cydA Deletion of 1210bp of the 1458bp cydA gene (in-frame deletion).  Moosa, Mizrahi & 
Warner (Unpublished) ∆cydAB Deletion of 2298bp of the 2499bp cydAB genes (in-frame deletion).  
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7.2 In vitro metabolite generation 
7.2.1 Human liver microsomes (HLM) and rat liver microsomes (RLM) 
Incubations were performed using a modified protocol based on,2 with human (pooled 
human mixed gender, Xenotech) and rat (male rat IGS, Xenotech) liver microsomes at a 
small scale to establish chlorpromazine (CPZ) metabolism and to identify the metabolites. 
10µM CPZ was incubated in 0.5mg/ml of microsomes and 100mM phosphate buffer (pH 7.4) 
with 5mM MgCl2. 1mM NADPH was added and incubation was carried out at 37°C with 
shaking for 1h. An equal volume of ice-cold acetonitrile was added to stop the reactions and 
to precipitate the proteins. After centrifuging the mixtures at 14000 x g for 30min, the 
supernatant was transferred to high performance liquid chromatography (HPLC) vials. 
Control samples with no NADPH, no microsomes and a T0 (time 0) sample were also 
included and processed in a similar way to the samples.  
 
7.2.2 Recombinant cytochrome P450 (CYP450) whole cells 
Whole cell incubations with CYP450s expressed in Escherichia coli: 2D6, 3A4, 2C9, 1A2 
were carried out as described.2,3 A colony of the bacteria containing the respective plasmid 
for expression of the enzymes was inoculated in autoclaved Luria-Bertani (LB) media 
supplemented with 100mg/ml ampicillin and incubated at 37°C with shaking for 16h. The 
culture was used to inoculate Terrific Broth media that contained 100mg/ml ampicillin, trace 
elements (2.5ml/L), 1mM thiamine and 0.5mM FeCl3. Incubation was carried out at 30°C 
with shaking for 7-8h. To induce the cells to start expressing the enzymes, 0.5mM δ-
aminolevulinic acid and 1mM isopropyl β-D-thiogalactopyranoside (IPTG) was added and 
further incubation was carried out for 48h. The cells were washed with 1 x phosphate buffer 
saline (PBS) several times with centrifuging then finally the pellet was used for the 
incubation of CPZ. As in the case of the microsomes, the same concentration of CPZ was 
incubated in 0.6g/L of the cells in 100mM phosphate buffer with glucose (10mg/ml) but the 
cofactor was not added. The advantage of using whole cells is that they do not require an 
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electron transport protein, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) 
which acts as a redox partner to the CYP450 enzyme.  
 
7.2.3 Bioengineered cytochrome P450 (CYP450) 21B3 
Bioengineered CYP21B3 (in E. coli) was also used to metabolize CPZ as described.4 A 5ml 
culture from a freezer stock was prepared and allowed to incubate at 37°C for 16h 
(overnight) with shaking. The culture was then added to 50ml LB media. Incubation was 
carried out for 16h to allow growth of E. coli cells to an OD600 2. Terrific media (2L) was 
prepared as described in section 7.2.2 and the pH was adjusted to 7.4, then autoclaved. The 
50ml culture was added to the 2L terrific media and the growth of the culture was performed 
to an OD600 0.35 in the bioreactor. 0.5mM δ-aminolevulinic acid was then added. At OD600 
0.56 the culture was induced with 1mM IPTG and growth continued for another 18h. The 
cells were washed in 1 x PBS and the pellet was then re-suspended in lysis buffer (5ml lysis 
buffer for 500ml culture) then 1mg/ml lysozyme, 2.5mM MgCl2, 500U DNase1 and 0.5mM 
CaCl2 were added. This mixture was incubated on ice for 30min with gentle shaking after 
which 0.5% 3-[(3-cholamidopropyl)-dimethylammonio]propanesulfonate (CHAPS) and 0.1% 
Triton X-100 were added. Incubation again was performed on ice for 30min with gentle 
shaking and the lysate was spinned at 17700 x g for 30min at 4°C to remove cell debris.  
 
10mM of CPZ (1.25µl) was added to 1.6µM of cells (25µl) in 0.1mM phosphate buffer (pH = 
8.25, 219µl) and 125mM hydrogen peroxide (H2O2, 5µl). The mixture was allowed to 
incubate at 37°C with shaking for 3h with addition of 5µl H2O2 after every 30min. The 
reaction was stopped with an equal amount of acetonitrile. The samples were spun at 14000 
x g for 15min at 4°C and the supernatant was filtered into HPLC vials. Two controls were 
included: a negative control that consisted of cells with no 21B3 enzyme (DH5α) and a 
positive control (drug but no cells). 
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7.2.4 Actinomycetes 
Incubations with actinomycetes were carried out based on a modified protocol as described.5 
Four strains of actinomycetes were used, Streptomyces griseus griseus (SGG), 
Streptomyces coelicolor (SC), Gordonia terrae (GT) and Nocardia gamkensis (NG).  Freezer 
stocks of the actinomycetes were used to inoculate a 500ml flask containing 100ml malt 
extract medium (2g dextrose, 1g malt extract, 1g yeast extract, 0.1g peptone, pH = 7 
adjusted using 1N NaOH /1N HCL). Incubation was carried out for 48h at 37°C with shaking 
at 250 x g. 200µl of the culture was transferred into 96 deep well plates and 0.5µl of 100mM 
CPZ was added. Two controls were included for each strain, cells with no drug and drug in 
media with no cells. The plates were then incubated at 30°C, 200 x g for 48h and the 
reactions were quenched using equal amounts of frozen acetonitrile. Centrifugation was 
carried out (section 7.2.1) and the supernatant was collected, filtered and analyzed on liquid 
chromatography - mass spectrometry (LC/MS).  
 
 7.3 Anti-mycobacterial screening 
 7.3.1 Broth microdilution assay/microplate alamar blue assay (MABA) 
Minimum inhibitory concentration (MIC99) for the various compounds tested, was determined 
as described.6 Briefly, a pre-culture of Mycobacterium smegmatis (Msm) (mc2155) was 
prepared from a glycerol stock and grown for 16h followed by a sub-culture grown to an 
OD600 0.6-0.8 (logarithmic phase) in filter-sterilized 7H9 media supplemented with 
10%OADC, 0.2% glycerol and 0.25% Tween 80 (20% in H2O) at 37°C with no shaking. The 
media was added to 96 microtitre well plates followed by addition of the drugs which were 
then serially diluted. Finally the culture (diluted x 1000) was added to the wells. The controls 
included media only and the solvent used to dissolve the drugs at a concentration 
corresponding to that of the working solutions of the drugs. Incubation was carried out at 
37°C with no shaking for 48h then resazurin dye was added to the plates. Further incubation 
was carried out for 24h in the same conditions.  
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In the same manner, Mtb (H37RvMa, or cytochrome bd oxidase knock-out mutant strains) 
glycerol stocks were used to prepare pre-cultures that were grown in 7H9 media, 
supplemented with 10%ADC, 0.2% glycerol and 0.25% Tween 80 (20% in H2O) (H37RvMa 
wild-type strain) or GAST/Fe (pH 6.6 glycerol-alanine-salts, with 0.05g of ferric ammonium 
citrate) minimum media (cytochrome bd oxidase mutant strains), for 4 days (OD600 0.8). The 
sub-culture was grown to log phase (OD600 0.6-0.8).  The sub-cultures of H37RvMa wild-type 
or cytochrome bd oxidase mutant strains were diluted x 1000 and x 100 respectively, then 
added to the wells. The plates were incubated for 14 days. MIC99 of the various drugs was 
then recorded. Drug susceptibility tests with spectinomycin (SPEC) Mtb mutants were 
carried out as described here, in 7H9 ADC media. All assays were repeated three times in 
duplicate. 
 
7.3.2 Synergistic drug combinations for TB therapy 
A two dimensional array of serial dilutions of two test compounds was prepared in 96 well 
plates and a mycobacterium culture prepared as described in section 7.3.1 was added to the 
wells. Incubations were carried out under the same conditions as described (section 7.3.1). 
Relative MIC99 concentrations in wells representing various ratios of the two compounds was 
then used for calculations to determine whether paired combinations exert inhibitory effects 
that are more than the sum of their effects alone (synergy). Cell viability was then 
determined and the fractional inhibitory concentration index (FICI) values which correspond 
to either compound (A or B) were defined as:7–9          
MIC99 of A (combination)/MIC99 of A (singly) + MIC99 of B (combination)/MIC99 of B (singly) 
The assays were repeated three times in duplicate. 
 
7.3.3 Determination of bactericidal versus bacteriostatic activities 
A pre-culture of Mtb (H37RvMa) was prepared from a glycerol stock followed by a sub-
culture grown to an OD600 0.2 (lag phase) in filter-sterilized 7H9 ADC media at 37°C with no 
shaking. CPZ and its metabolites were then added to a 96-well plate followed by a 2-fold 
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serial dilution. Combinations of CPZ or its metabolites with antituberculosis (anti-TB) drugs 
were prepared on the best synergy achieved against Mtb. The culture was diluted (x 1000) 
and was added to the 96-well plates containing the drugs. Part of the culture was transferred 
to 7H10 solid media supplemented with 10% OADC and 0.5% glycerol (agar media), for 
colony forming units per milliliter (CFU/ml) counting (0 time control). The plates were then 
incubated for 14 days at 37°C. On the 14th day, 100µl of the MIC99 wells, the subsequent 
wells (control) and wells with no drugs (control) were plated in required dilutions on standard 
7H10 solid media plates followed by further incubation at 37°C for 4 weeks. CFU/ml counts 
were then calculated for determination of bactericidal or bacteriostatic effect. All assays were 
repeated twice in duplicate. 
 
7.3.4 CPZ or its metabolites spontaneous resistant mutant strain generation 
A pre-culture of Mtb (H37RvMa) was prepared from a glycerol stock followed by a sub-
culture grown to an OD600 0.6-0.8 (logarithmic phase) in filter-sterilized 7H9 ADC media at 
37°C with no shaking. The culture was centrifuged for 10min at 18°C and 3500 x g and the 
pellet was re-suspended in 1ml 7H9 OADC media. 100µl of the 1ml culture was serially 
diluted and plated onto standard 7H10 solid media plates with no drug. Similar volumes were 
plated onto standard 7H10 solid media plates containing 5 x, 10 x, 15 x or 20 x MIC99 
concentrations of CPZ, 7-hydroxyCPZ (M2) and nor-CPZ (M5). The plates were prepared in 
duplicates and incubation at 37°C for 4 weeks.  
 
7.3.5 qRT-PCR analyses of cydA expression 
7.3.5.1 Extraction of RNA from treated Mtb culture 
A preculture of Mtb (H37RvMa) was prepared in 7H9 ADC media followed by sub-cultures 
(25ml) that were grown to logarithmic phase (OD600 0.6) at 37°C. The cultures were then 
treated with 140µM CPZ or the metabolites.10 RNA was extracted after 6h of incubation at 
same conditions, with FastRNA ProTMblue kit (MP Biomedicals) as per the manufacturer’s 
instructions. Briefly, the cultures were pelleted at 3500 x g for 12min at 18°C and the 
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supernatant discarded. The pellets were re-suspended in 1ml of lysing matrix B and 
transferred into blue-cap tubes. The samples were processed in the FastPrep® 
homogenizer instrument (IEPSA Medical Diagnostics) for 40sec at a setting of 6.0 followed 
by centrifugation at 12000 x g for 5min at 4°C. The supernatant was carefully transferred into 
clean 1ml tubes and the RNA was extracted using chloroform (CHCl3) then centrifuged at 12 
000 x g for 5min at 4°C.  RNA in the upper phase was then transferred into clean 1ml tubes 
and cold 500µl absolute ethanol was added. The mixture was left to stand for 30mins in -
20°C. Centrifugation followed for 15min at 12000 x g and the pellet formed was washed 
again in 70% ethanol. The RNA was dried then re-suspended in 50µl DEPC-treated RNase-
free water and stored at -80°C (Appendix 8A). 
 
7.3.5.2 DNase treatment 
DNase treatment was carried out on each 3µg RNA sample with 2U of TURBO™ DNase 
(Ambion®) according to the manufacturer’s instructions for 30min initially, followed by 
addition of 2U of DNase and incubated for further 30min. The RNA was subsequently 
cleaned up using RNeasy MiniKit (Qiagen). The quantity of RNA was determined using a 
Nanodrop 2000c Spectrophotometer (Thermo Scientific). All samples were tested for 
residual DNA by polymerase chain reaction (PCR) using a FastStart Taq DNA polymerase 
kit (Roche Diagnostics GmbH) and confirmed to be free of DNA when no amplified product 
could be detected after 34 cycles. The PCR products were visualized on 1% agarose gel 
prepared in Tris/Acetate/EDTA (TAE) buffer (Appendix 8B). 
 
7.3.5.3 Design of cydA gene primers 
The cydA gene sequence was obtained from TB Genomes Database (TB DB) and used to 
design the probe and the primers using Primer Express 3.0.1 (Applied Biosystems software). 
The designed primers/probes for cydA and sigA (Table 7.2) were obtained from Applied 
Biosystems Oligonucleiotide® Custom Primers & Probes, Life Technologies.  
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Table 7.2: cydA and sigA primers and probes for qRT-PCR 
Primers/probes for cydA & sigA Sequence 
cydARTF (forward) 5’-CGATCTGCAGCAGGAATACCA-3’ 
cydARTR (reverse) 5’-AAG AGGTTGGGCCGGTAGTC-3’ 
cydA probe 5’-CAGCGCTTCGGACCA-3’ 
sigARTF (forward) 5’-CGAGCCGATCTCGTTGGA-3’ 
sigARTR (reverse) 5’-TTCGATGAAATCGCCAAGCT-3’ 
sigA probe 5’-ACGAGGGCGACAGC-3’ 
 
Conditions for the PCR reaction were set according to the instructions provided in the DNA 
polymerase kit but with slight modifications, on a C1000TM Thermocyler (Bio-Rad) (Table 
7.3).   
 
Table 7.3: PCR reaction conditions 
Reaction step Temperature (°C) Time  
Initialization  95 3min 
Denaturation 95 30s 
Annealing  60 30s   x 34 cycles 
Amplification/Elongation 
72 30 s 
72 5min 
 
7.3.5.4 Synthesis of cDNA 
100ng of the DNase treated RNA was used to synthesize cDNA for each sample using a 
MMLV High Performance Reverse Transcriptase kit (Epicentre) as per the manufacturer’s 
protocol. Random hexamer primers were used in this case. A negative control (no reverse 
transcriptase enzyme) was included for each RNA sample and the conditions for this 
reaction on a C1000TM Thermocyler (BioRad) were as shown on Table 7.4.  
 
Table 7.4: cDNA synthesis reaction conditions 
Reaction step Temperature (°C) Time  
Annealing (RNA + the hexamer random primer) 65 2min (then chill on ice for at least 1 min) 
Incubation (annealed RNA primer + master mix) 25 10min 
First strand reaction 
37 1h  
85 5min 
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7.3.5.5 Real-time PCR (RT-PCR) 
cDNA obtained for each sample including the negative controls were used in RT-PCR on a 
PikoReal 96 Real Time PCR System (Thermo Scientific), to amplify a portion of cydA gene 
in a reaction that was carried out using Taqman Universal MMix II with UNG (Life 
Technologies) according to the manufacturer’s instructions and normalized to levels of sigA 
(Rv2703), a housekeeping gene whose expression is reported to remain constant in various 
growth phases.11 The conditions that were used for this reaction are shown on Table 7.5. 
The average expression levels, normalized to sigA, and standard deviations were calculated 
using data from three technical replicates of two independent experiments. 
 
Table 7.5: RT-PCR reaction conditions 
Reaction step Temperature (oC) Time  
UNG incubation 50 2 min  
AmpliTaq gold enzyme activation 95 10 min 
PCR 
95 15s  x 40 cycles  
60 1min 
 
7.3.6 Spectinomycin (SPEC) spontaneous mutant generation  
An Mtb (H37RvMa) culture was prepared as described in section 7.3.4 and plated onto 7H10 
solid media prepared with 5 x MIC99 concentration of SPEC. After 4 weeks’ incubation, the 
number of mutant colonies was recorded and the frequency of mutation was determined in 
relation to the colonies obtained in plates with no drug. Colonies were randomly selected 
and grown in 7H9 ADC media and the MIC99 of SPEC and other drugs were determined 
again using cultures prepared from the mutant colonies.  
 
7.3.6.1 Isolation of genomic DNA from mycobacteria  
For isolation of genomic DNA from H37RvMa and SPEC-resistant (SPECR) mutant Mtb 
strains, seed culture was prepared by growing strains in 7H9 OADC media at 37°C with 
shaking to OD600 0.8. The cells were sub-cultured by diluting 50-fold in fresh 7H9 ADC media 
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and grown to OD600 0.8. 10ml of culture was harvested and cells were heat killed at 85°C for 
2h followed by centrifugation at 3000 x g for 10min. The pellets were washed twice with 10ml 
ice cold PBS and finally re-suspended in 1ml Tris/EDTA (TE) buffer supplemented with 
400μl of 50mg/ml lysozyme stock and 10μl of 10mg/ml RNAase. The mixture was then 
incubated overnight at 37°C. After incubation, 1% SDS and 100μg/ml proteinase K were 
added to the suspension and incubated at 65°C for 2h. The suspension was centrifuged at 
3000 x g for 30min to pellet cell debris. The pellet was discarded and clear supernatant was 
collected in a 15ml tube. An equal volume of buffered phenol was added to the supernatant, 
mixed gently and the two phases were separated by centrifugation at 12000 x g for 10min. 
The upper aqueous layer was removed carefully and extracted twice with CHCl3:isoamyl 
alcohol (C5H12O) solution (24:1). DNA in the aqueous phase was precipitated by the addition 
of 0.1 volume of 3M sodium acetate and equal volume of isopropanol and pelleted by 
centrifugation at 12000 x g for 15min at 4°C. The pellet was washed twice with 70% ethanol, 
air dried and suspended in 50μl TE buffer (pH 8.0). 
 
7.3.6.2 DNA amplification by PCR  
PCR reactions were set in 25μl volume using 50ng of template DNA, 0.5μM of each primer, 
200μM of each dNTPs, 1unit of Phusion Taq DNA polymerase in PCR buffer with 1.5-2.0mM 
MgCl2.  
 
7.3.6.3 Purification of PCR amplified product  
The DNA fragment was excised from the gel and extracted using gel extraction kit (Qiagen). 
Briefly, the excised gel was weighed and 3 volumes of QG buffer was added to one volume 
of gel, mixed properly and incubated at 50°C for 10min with slight shaking. After the 
dissolution of gel, one volume of isopropanol was added and mixed properly. The sample 
was transferred in QIAquick spin column and centrifuged. The flow-through was removed 
and 500μl of QG buffer was added in column. Centrifugation of the column followed at 
12000 x g for 1min. The column was washed with 750μl of buffer PE followed by 
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centrifugation at 10000 x g for 1min. The flow-through was discarded and column was extra-
centrifuged for 1min for complete removal of ethanol. The column was placed in a fresh tube 
and 55μl of DEPC-treated RNase-free water was added followed by incubation for 5min. The 
column was then centrifuged for 1min and eluted DNA was collected in fresh tube. 
 
7.3.6.4 Nucleotide sequencing of cloned insert  
The sequencing reaction of 20μl final volume contained: PCR product (100ng), 5 pmol 
primer (Table 7.6), Big Dye Terminator reaction mix 8μl, milli-Q water to final volume of 20μl.  
 
Table 7.6: Primers for sequencing 
16SrRNA Primer 
rrs_seqF1  5’-CCGAAGCGGGCGGAAACAA-3’ 
rrs_seqF2 5’-GCGAACGGGTGAGTAACAC-3’ 
rrs_seqF3 5’-AATTACTGGGCGTAAAGAG-3’ 
rrs_seqF4 5’-GTTAAGTCCCGCAACGAGC-3’ 
rrs_seqR1 5’-TTACTGCCCAGAGACCCGC-3’ 
rrs_seqR2 5’-TGATCTGCGATTACTAGCG-3’ 
rrs_seqR3 5’-ACCACTATCCAGTTCTCAA-3’ 
rpSE Primer 
rpsE seqF1  5’-GGCGTGCCGGGTGACAAAA-3’ 
rpsE seqF1 5’-GCTTTGGTCATCGTGGGCG-3’ 
rpsE seqR1 5’-CCACATTGATCGCGTTGTC-3’ 
rpsE seqR2 5’-CTATGTCTTCCCTCCGGTC-3’ 
 
The reaction mixture was mixed properly and subjected to the PCR cycle as indicated in 
Table 7.7. 
  
Table 7.7: PCR reaction conditions 
Reaction step Temperature (°C) Time  
Initialization denturation 95 4 min 
Denaturation 94 20s 
Annealing  50 20s   x 30 cycles 
Amplification/Elongation 60 5s 
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The sequencing reaction product was then submitted to the sequencing facility at 
Stellenbosch University, South Africa, to run the capillary electrophoresis. The obtained 
results were analyzed using CLC Main Workbench 6.0.2. 
 
 
7.3.6.5 Fitness cost of SPECR mutant strains 
A preculture of H37RvMa and SPECR mutant Mtb strains were prepared in 7H9 ADC media 
from freezer stocks followed by sub-cultures (25ml, in triplicates) prepared with very low 
inoculums (OD600 0.005). In two independent experiments, the growth kinetics of SPEC 
mutant strains were monitored in 7H9 ADC media at 37°C for 7 days by recording the OD600. 
 
7.4 Structural characterization of metabolites 
An Agilent 1200 Rapid HPLC system coupled to an AB SCIEX 4000 QTRAP® mass 
spectrophotometer was used. A kinetex C18 HPLC column (150mm x 2.1mm, packed with 
2.6µM fused core particles) was used for all analysis with a mobile phase flow rate of 
0.4ml/min and a column temperature of 40°C. The mobile phase used in all experiments 
consisted of 5mM ammnonium formate buffer. Mobile phase A was mainly aqueous, 
consisting of 5% acetonitrile at pH 3 (pH adjusted using fomic acid), while mobile phase B 
consisted of 95% acetonitrile. Identification of the metabolites formed by all the systems was 
carried out using IDA-ESI experiments. A hybrid triple quadrupole-linear ion trap (QqQLIT) 
system (MS/MS) was used for comprehensive study of fragmentation mechanisms. All 
Nuclear Magnetic Resonance (NMR) experiments were performed on a 300MHz Bruker 
NMR spectrophotometer to confirm the structure of the metabolites.12,13 
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7.5 Scaled-up CPZ metabolites 
7.5.1 7-HydroxyCPZ (M2) 
                                                 
                                                              C17H19ClN2OS 
                                                             Mol. Wt: 334.86 
 
7-hydroxy CPZ (M2) was purchased from Sigma Aldrich. LC/MS analysis of M2 generated 
MH+ of the compound at m/z 335 and the retention time of this compound corresponded to 
M2 in the HLM incubation sample of CPZ (Figure 7.1, Appendix 3A). 
 
 
Figure 7.1 XIC chromatogram of the purchased standard, 7-hydroxyCPZ (M2) compared to the metabolite 
formed in HLM incubation sample of CPZ 
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7.5.2 CPZ-N-oxide (M3)  
                                                
                                                          C17H19ClN2OS 
                                                         Mol. Wt: 334.86 
 
m-CPBA (1.5g, 0.0084 mol) was added portion wise at 0°C to a solution of CPZ (2g, 0.0056 
mol) in CH2Cl2 (50ml) and 4N NaOH solution (400µl) and the reaction mixture was stirred for 
4h. The solvent was evaporated in vacuo before setting the pH of reaction at 10 using 4N 
NaOH solution and extracted with CH2Cl2 (3 x 15ml). The organic extracts were dried over 
MgSO4 and concentrated under reduced pressure. Purification through column 
chromatography afforded target compound as oil (0.78g, 40%); Rf 0.35 (15% MeOH-
CH2Cl2); 1H NMR (400MHz, CDCl3) δ 7.17 (m, 2H, ArH), 7.04  (d, J = 8.20 Hz, 1H, ArH), 
6.92 (m, 4H, ArH), 4.02 (t, J = 6.30 Hz, 2H, CH2N), 3.34 [t, J = 7.52 Hz, 2H, CH2N(CH3)2], 
3.05 [s, 6H, N(CH3)2], 2.36 (m, 2H, CH2CH2CH2) (Appendix 4A); 13C NMR (100MHz, CDCl3) 
δ 128.2, 127.8, 127.7, 123.5, 122.9, 116.3, 68.4, 58.8, 44.9 and 21.3; LC/MS analysis 
generated MH+ of the compound at m/z 335 and the retention time of this compound 
corresponded to M3 in the HLM incubation sample of CPZ hence M3 was confirmed to be 
CPZ-N-oxide (Figure 7.2, Appendix 4B). 
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Figure 7.2 XIC chromatogram of CPZ-N-oxide (M3) synthesized compared to the metabolite formed in HLM 
incubation sample of CPZ 
 
 
7.5.3 CPZ sulfoxide (M1) 
                                                          
                                         C17H19ClN2OS 
                                                                   Mol. Wt: 334.86  
 
The target compound (0.2g, 10%) was obtained as side product in the reaction that led to 
the formation of CPZ-N-oxide (M3). On thin layer chromatography (normal phase silica gel) 
and column chromatography, it eluted after the N-oxide (M3). The structure was confirmed 
using NMR and LC/MS data (Appendices 2A-B). Rf 0.3 (15% MeOH-CH2Cl2); 1H (400MHz, 
CDCl3) δ 7.94 (m, 1H, ArH6), 7.89 (d, J = 8.2 Hz, 1H, ArH4), 7.63 (m, 1H, ArH8), 7.54 (m, 2H, 
ArH7), 7.30 (m, 1H, ArH1), 7.24 (dd, J = 8.2 and 1.8 Hz, 1H, ArH9), 4.42 (m, 2H, CH2N), 2.75 
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[t, J = 7.2 Hz, 2H, CH2N(CH3)2], 2.46 ([s, 6H, N(CH3)2], 2.25 (m, 2H, CH2CH2CH2); 13C 
(100MHz, CDCl3) δ 133.1, 132.4, 131.2, 122.7, 122.3, 116.3, 55.5, 45.4, 44.2 and 23.9; 
LC/MS analysis generated MH+ of the compound at m/z 335 but unlike the N-oxide (M3) the 
retention time of this compound (5.20) corresponded to M1 in the HLM incubation sample of 
CPZ (Figure 7.3). 
 
 
Figure 7.3 XIC chromatogram of sulfoxide (M1) synthesized compared to the metabolite formed in HLM 
incubation sample of CPZ 
 
7.5.4 Nor-CPZ (M5) 
 
                                        
                 C16H17ClN2S 
                                                            Mol. Wt: 304.84 
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Solution of CPZ-N-oxide (M3) (0.6g, 0.0018 mol) in MeOH (10ml) was cooled to 0°C 
followed by an addition of a solution of FeSO4 (1g, 3.59 mol) in MeOH (1ml). The reaction 
was stirred at 0°C for 3h. The solvent was removed under reduced pressure to obtain 
reddish brown solid, which was dissolved in 0.1M EDTA solution (1.86g in 50ml H2O) at pH 
10 adjusted using NH3 solution. Extraction was carried out using CH2Cl2 (3 x 15). Organic 
extracts were dried over anhydrous MgSO4 and removed under reduced pressure. 
Purification through column chromatography afforded products as oil (65mg, 11%); Rf 0.3 
(15% MeOH-CH2Cl2); 1H (400MHz, CDCl3) δ 7.2 (m, 2H, ArH6,8), 7.09 (m, 1H, ArH4), 6.96 
(m, 4H, ArH1,3,7,9), 4.03 (t, J = 6.5 Hz, 2H, CH2N), 2.95 (t, J = 7.1 Hz, 2H, CH2NCH3), 2.51 (s, 
3H, NCH3), 2.21 (m, 2H, CH2CH2CH2) (Appendix 6A); 13C (100MHz, CDCl3) δ 128.2, 127.8, 
127.7, 123.4, 122.8, 116.1, 47.9, 44.9, 34.1 and 24.6; LC/MS analysis of M5 gave a m/z 305 
and retention time 6.61 corresponding to the one in the HLM incubation of CPZ (Figure 7.4, 
Appendix 6B). 
 
 
Figure 7.4 XIC chromatogram of nor-CPZ (M5) synthesized compared to the metabolite formed in HLM 
incubation sample of CPZ 
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7.5.5 Nor-CPZ sulfoxide (M6b) 
                                                         
                                                                   C16H17ClN2OS 
                                                                  Mol. Wt: 320.84 
 
Nor-CPZ (M5) (0.2g, 0.0005 mol) was oxidized using m-CPBA (0.124g, 0.0007 mol) in a 
reaction that was carried out as described for CPZ-N-oxide (M3). Purification on column 
chromatography yielded nor-CPZ sulfoxide (M6b) (46.7mg, 30%). 0.17 (80% MeOH-
CH2Cl2); 1H (400MHz, CDCl3) δ 7.86 (m, 2H, ArH6,8), 7.57 (m, 1H, ArH4), 7.25 (m, 4H, 
ArH1,3,7,9), 4.35 (m, 2H, CH2N), 2.79 (t, J = 6.8 Hz, 2H, CH2NCH3), 2.48 (s, 3H, NCH3), 2.11 
(m, 2H, CH2CH2CH2) (Appendix 7A); 13C (100MHz, CDCl3) 133.2, 132.2, 131.0, 122.8, 
122.4, 116.6, 47.3, 45.2, 34.6 and 24.7; LC/MS analysis of M6b gave a m/z 320.9 at 
retention time 5.26 corresponding to the one in the HLM incubation of CPZ (Figure 7.5, 
Appendix 7A). 
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Figure 7.5 XIC chromatogram of nor-CPZ sulfoxide (M6b) synthesized compared to the metabolite formed in 
HLM incubation sample of CPZ 
 
7.5.6 CPZ-N-S-dioxide (M4b) 
                                                
                                                          C17H19ClN2O2S 
                                                          Mol. Wt: 350.86 
 
CPZ sulfoxide (M1) (0.4g, 1.1 mol) was oxidized using m-CPBA (0.3g, 1.7 mol). The reaction 
was carried out at 0°C in CH2Cl2 (50ml) and 4N NaOH solution (400 µl) for 4h with stirring.  
Extraction and purification was carried out as described for CPZ-N-oxide (M3) yielding CPZ-
N-S-dioxide (M4b) as a white crystalline solid (0.241g, 65%); Rf 0.17 (20% MeOH-CH2Cl2); 
M. pt. 105-107°C; 1H NMR (400MHz, CDCl3) δ 7.88 (m, 2H, ArH6,8), 7.60  (d, J = 8.20 Hz, 
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1H, ArH4), 7.28 (m, 4H, ArH1,3,7,8), 4.56 (m, 2H, CH2N), 3.30 [t, J = 7.6 Hz, 2H, CH2N(CH3)2], 
3.01 [s, 6H, N(CH3)2], 2.25 (m, 2H, CH2CH2CH2) (Appendix 5A); 13C(100MHz, CDCl3) δ 
133.1, 131.9, 130.7, 122.9, 122.6, 117.2, 67.0, 59.2, 44.3 and 21.8; LC/MS analysis of M4b 
gave a m/z 351.1 and retention time 5.98 corresponding to the one in the HLM incubation of 
CPZ (Figure 7.6, Appendix 5B). 
 
 
Figure 7.6 XIC chromatogram of CPZ-N-S-dioxide (M4b) synthesized compared to the metabolite formed in RLM 
incubation sample of CPZ 
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Appendix 1A: 1H NMR of chlorpromazine (CPZ) 
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Appendix 1B: MS/MS spectrum of CPZ  
 
Parent ion: m/z - 318.8 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 6.769 min from Sample 6 (CPZ HLM) of 5mM NH4formate PH3 Kinetex C18 15cm.wiff (Turbo Spray), Centroided Max. 7.2e8 cps.
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Appendix 2A: 1H NMR of CPZ sulfoxide (M1) 
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Appendix 2B: MS/MS spectrum of CPZ sulfoxide (M1)  
 
Parent ion: m/z – 335.1 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 6.923 min from Sample 6 (CPZ HLM) of 5mM NH4formate PH3 Kinetex C18 15cm.wiff (Turbo Spray), Centroided Max. 7.1e7 cps.
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Appendix 3A: MS/MS spectrum of 7-hydroxyCPZ (M2) 
 
Parent ion: m/z – 335.0 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 5.999 min from Sample 6 (CPZ HLM) of 5mM NH4formate PH3 Kinetex C18 15cm.wiff (Turbo Spray), Centroided Max. 5.0e8 cps.
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Appendix 4A: 1H NMR of CPZ-N-oxide (M3) 
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Appendix 4B: MS/MS spectrum of CPZ-N-oxide (M3) 
 
Parent ion: m/z – 335.0 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 6.942 min from Sample 9 (CPZ RLM) of 5mM NH4formate PH3 Kinetex C18 15cm.wiff (Turbo Spray), Centroided Max. 8.2e8 cps.
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Appendix 5A: 1H NMR of CPZ-S-N-dioxide (M4b) 
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Appendix 5B: MS/MS spectrum of CPZ-N-S-dioxide (M4b) 
 
Parent ion: m/z – 351.1 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 6.034 min from Sample 7 (50µM CPZ dihydroxy) of CPZ dihydroxy Rt check.wiff (Turbo Spray), Centroided Max. 2.9e8 cps.
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Appendix 6A: 1H NMR of nor-CPZ (M5) 
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Appendix 6B: MS/MS spectrum of nor-CPZ (M5) 
 
Parent ion: m/z – 305.1 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 6.645 min from Sample 1 (nor-CPZ 50µM 50% ACN) of CPZ metabolite mass check.wiff (Turbo Spray), Centroided Max. 8.4e8 cps.
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Appendix 7A: 1H NMR of nor-CPZ sulfoxide (M6b) 
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Appendix 7B: MS/MS spectrum of nor-CPZ sulfoxide (M6b) 
 
Parent ion: m/z – 321.0 
 
 
 
 
 
 
 
 
 
 
 +EMS: Exp 1, 5.313 min from Sample 1 (Compound A 50µM) of Mass check.wiff (Turbo Spray), Centroided Max. 1.0e9 cps.
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Appendix 8A: Extracted RNA samples before DNase treatment 
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Appendix 8B: PCR of the RNA samples after DNase treatment 
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Appendix 9A: gDNA isolated from SPECR Mtb mutant strains 
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Appendix 10A: Morphology of SPECR Mtb mutant strains 
 
 
